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ABSTRACT 
For children with epilepsy, therapeutic drug monitoring (TDM) of antiepileptic drugs (AEDs) 
is essential for treatment. TDM monitoring requires two visits to a health care unit, first for 
collection of the blood sample before the morning dose and a few days later the family will 
travel once again to see the pediatrician. For this patient group, blood from a fingerprick, 
collected on a filter paper at home and sent by mail to the laboratory as a dried blood spot 
(DBS), could be beneficial and facilitate everyday life. 
The aim of this thesis has been to investigate whether it is possible to use DBS as a matrix for 
TDM of common AEDs interchangeably with plasma. A second aim was to study the DBS 
self-sampling process, to see if guardians of children with epilepsy were able to collect DBS 
samples with sufficient quality and find what factors influenced a successful collection.  
Precise and robust liquid chromatography tandem mass spectrometry (LC-MS/MS) methods, 
using DBS as a matrix, were developed and validated for four major AEDs. The methods met 
acceptance criteria from the European Medicine’s Agency (Paper I and III). Patient samples 
were collected from children treated with carbamazepine (CBZ), lamotrigine (LTG), 
levetiracetam (LEV) and valproic acid (VPA) to perform bridging studies and compare DBS 
concentrations with plasma.  
Results concluded that a factor was needed to convert DBS concentrations for CBZ and VPA, 
to estimated plasma concentrations (Paper II). In the clinical evaluation, only 4 out of 190 
comparisons of DBS and plasma concentrations resulted in different dose recommendations 
The DBS self-collection process was evaluated by comparing the quality of samples obtained 
from a group of pediatric nurses with a group of guardians to children with epilepsy. Results 
showed that guardians could collect acceptable quality DBS samples from their children 
(Paper IV).  
A mixed method study showed that most of the guardians (80%) found self-sampling at home 
desirable after a training session. Factors for successful self-sampling were; high motivation, 
prepared guardians, flexible education with support from a nurse, effective communication 
between the guardian and the child and that guardians were willing to take on the role as 
performers (PaperV). 
The conclusion was that children with epilepsy and their guardians can use DBS as an 
alternative matrix for self-sampling, and that DBS concentrations of CBZ, LTG and VPA can 
be analyzed for TDM purposes. DBS for LEV can be collected for compliance queries or for 
patients where the alternative is no sample at all. These patients are monitored closely and in 
cases where DBS samples collected at home result in a concentration deviating from the 
expected or at risk of adverse effects, it is recommended to also collect a plasma sample.  
Guardians of children with epilepsy are interested in performing self-sampling and by being 
offered DBS self-collection at home these families can save time and have lower stress levels.  
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1 PREFACE 
The main focus of this thesis has been to explore and investigate the possibility to use blood 
collected on filter paper or dried blood spot (DBS) as a matrix for quantification of 
antiepileptic drugs (AEDs), Figure 1. For patients with epilepsy, treatment with AEDs and in 
relevant cases therapeutic drug monitoring (TDM) with individual doses are essential for 
effective treatment. DBS is a matrix that has the potential to be utilized at home for capillary 
blood self-sampling, and it can facilitate the everyday life for children with epilepsy and their 
families. 
 
Figure 1. Blood spot collection on a filter paper, DBS 
Photo, Johanna Linder. 
Method development and validation for DBS has been the main objective in paper I and III. 
Adaption to the routine laboratory by developing rapid, simple and robust methods with 
sample traceability has been a main goal. 
Bridging studies between measured concentrations in capillary DBS and capillary plasma, 
was the main objective in paper II and IV. Guardians (parents or someone responsible for the 
child) collected DBS samples from their children with the help of an instruction video1 and 
support from a nurse.  
In paper IV and V the patient perspective was investigated. Could guardians collect DBS 
from their children with acceptable quality? What did they experience during the collection 
process and what opinions did they have to self-sampling at home? 
From my own professional perspective as a clinical biomedical scientist, the quality in all 
steps from sample collection to the final delivered result, is an important aspect in 
laboratory analysis. This comprehends good repeatability, credibility and trustworthiness. 
Also my earlier professional experience as a teacher, with knowledge on the importance of 
the presentation of information and education, has influenced this work. The presentation of 
the work in this thesis is discussed from three different perspectives. The laboratory 
perspective, the clinical perspective -and the patient perspective.  
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2 INTRODUCTION 
2.1 DEVELOPMENT OF DRIED BLOOD SPOT SAMPLING: A HISTORICAL 
PERSPECTIVE 
Blood is collected for a diverse range of investigations and analyses to check physiological 
and biochemical states related to health status or treatment. The golden standard for blood 
collection is whole blood collected as fresh venous blood in collection tubes, with the option 
for further processing of plasma or serum when needed. 
The filter paper matrix for the collection of blood samples, has been and is still of high 
relevance, due to many advantages and its diverse possible applications. Good sample 
stability over a wide temperature range and collection by non-professional health care 
workers, made collection possible in developing countries and regions far from hospitals. 
DBS sampling has been used for a diverse range of purposes as for example newborn 
screening for metabolic disease, human immunodeficiency virus (HIV) surveillance, clinical 
chemistry, forensic science, toxicology, biomarker development, drug discovery, human 
epidemiological and environmental population studies2. 
By the end of the 19th century, the Norwegian physician and scientist Ivar Christian Bang 
(1869-1918) experimented with micromethods for the sampling of blood glucose with filter 
paper-based matrix in his laboratory3 in Uppsala and Lund, Sweden. Already then, he 
criticized methods that required large amounts of blood, by stating: “Certainly we know many 
methods for studying the blood in many directions, and our knowledge of blood is still a terra 
incognita. For determining blood constituents if one could provide methods which require no 
more blood than can be drawn from the tip of a finger, or the ear vein of a rabbit, it would 
become possible to explore an inconceivable number of the finer processes of the blood and 
the cells, with results which a priori are unpredictable.” 3 
In 1963 Dr. Guthrie with his assistant A. Susi worked at Buffalo Children’s Hospital in 
Buffalo, New York and was specifically interested in the diseases of mentally disabled 
children. They invented a method where blood on filter paper was used to measure 
phenylalanine levels for detecting phenylketonuria in newborns4. Since then, screening of 
genetic metabolic disorders in newborns has been done throughout the world, collecting 
drops of blood onto a filter paper by heel or finger stick5,6.  
Historically, DBS methods were qualitative, until the development of liquid chromatography 
coupled to tandem mass spectrometry (LC-MS/MS)7 The improved sensitivity with the LC-
MS/MS platform made small amounts of blood in the microliter ranges enough for analysis. 
One of the first methods based on LC-MS/MS was developed in 1990 for acylcarnitine 
profiling8. Therapeutic drug monitoring (TDM), meaning analysis and evaluation of drug 
concentrations for the optimization of individual patient drug treatment, has been one of the 
main areas where DBS methods have been developed2. A method for measuring 
concentrations of antiretroviral drugs in TDM was developed in 20059. Since then, published 
DBS methods for different drugs and TDM have been steadily increasing. 
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The history of using DBS at the Clinical pharmacology laboratory, Karolinska University 
Hospital, Huddinge, started in 1985 when the tropical clinical pharmacology research group 
developed and used filter paper methods for pharmacokinetic and clinical field studies of 
chloroquine using high performance liquid chromatography (HPLC-UV) methods10. Later 
other DBS methods for assay of field studies were developed11–13 . 
DBS as an alternative matrix for TDM is promising and desirable since it may be possible for 
patients to sample themselves at home and send the DBS sample by mail for analysis at the 
TDM laboratory14. This may shift the balance in health care by patient involvement and 
increased patient autonomy15,16. 
2.2 PROPERTIES OF DRIED BLOOD SPOTS (DBS) 
There are many advantages associated with the use of DBS as a matrix, seen from all 
perspectives, laboratory, clinical, patient and society. One advantage is the minute amount of 
blood sampled compared to venous sampling. For pharmacokinetic studies in animals the 
numbers of animals required could be reduced by ~ 60% if DBS were used as matrix 
replacing traditional blood collection in sample tubes14, which would contribute to more 
ethical animal testing17. For neonatal care and blood collection the volume of blood collected 
is particularly important. For a premature newborn baby, the volume of blood in a normal 
blood test corresponds to as much as 0.3 to 1.3% of their total blood volume, while 
corresponding roughly to 0.01% of the total blood for an adult. Only 20-50 µL are required 
for a DBS, compared to 0.5 mL for a micrrotube or 5 mL for collection in a traditional 
venous tube.  
From a patient perspective, capillary sampling is less invasive which explains why it is 
preferred by many patients18–20. DBS sampling can also be performed at home by the patient 
or a non-professional carer with increased autonomy and reduced costs associated with 
transport, personnel and material15. Self-sampling at home is suitable for clinical and large-
scale studies requiring multiple sampling, since it becomes easier and more time efficient for 
participants21. 
From a laboratory perspective there are advantages when using DBS as matrix instead of 
plasma or whole blood. It is a dry and less infectious matrix for transportation and handling 
as compared to blood or plasma22–24. DBS cards can usually be transported and stored at 
room temperature with no requirements of energy-consuming cooling-packages, refrigerators 
or freezers. Transportation costs, carbon dioxide and waste products can be reduced 24. 
Calculations have shown that as much as 100 000 € could be saved during the shipping 
process in a clinical trial by sending samples as DBS instead of plasma samples that have to 
be transported on dry ice21. In most cases, DBS samples can be stored for longer periods of 
time with little or no degradation of the drugs7. 
From a societal perspective, DBS sampling has the potential to better meet the United 
Nations sustainable development goals25 with reduced transportation, energy savings, less 
waste materials and equal access to health care. 
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2.2.1 Whole blood versus plasma 
The drug concentration of AEDs in TDM is commonly measured in plasma26. Sample 
collection for TDM purposes is routinely performed as venous sampling (capillary in 
children) by nurses at the hospital or at an out-patient clinic. The main arguments for 
measuring in plasma have traditionally been; ease of storage, suitability for chemical analysis 
and homogeneity of plasma compared to clotted blood. Physiological considerations have 
been the main argument for measuring drug concentration in whole blood27,28. Evaluation of 
the variability of unbound fraction and the blood-to-plasma concentration (see section 2.4.2) 
is recommended before deciding whether to use plasma or whole blood for analysis of a 
specific drug27. 
2.2.2 Composition of blood 
Whole blood consists of approximately 45% blood cells and 55% plasma. The hematocrit 
(Hct), see section 4.3.4, is a measure of volume of the erythrocytes and varies with sex, age 
and health status. The red blood cells or erythrocytes are the main part of the blood cells and 
have a diameter of 6-8 µm, a thickness of 2-3 µm and a biconcave disc shape that can tolerate 
deformation which is necessary for passing through the capillaries29,30. 
Leukocytes and thrombocytes make up approximately 1% of the blood volume. When blood 
is centrifuged, the erythrocytes are packed at the bottom and the plasma at the top with a 
buffy coat of leukocytes and thrombocytes in the middle. Plasma contains water, ions (Na+, 
K+, Ca2+, Mg2+, Cl-, HCO3
-), energy substrates (glucose, fatty acids, ketone bodies, amino 
acids), metabolites (ammonia, urea, creatinine, bilirubin), proteins, lipoproteins, hormones 
and clotting factors. The most abundant proteins are albumins, globulins and fibrinogen30. 
Capillary blood is a mixture of venous and arterial blood and measures for pH, glucose, and 
blood gases are somewhere in between these two31. A fingerprick collection of capillary 
blood, is probably closer to arterial blood than venous blood, due to the relatively higher 
pressure on the arterial side32. Comparison of endogenous substances between venous and 
capillary blood have shown differences of less than 5%33. Differences between capillary and 
venous drug concentrations can be seen shortly after drug administration but are unlikely if 
samples are taken as trough concentrations (just before the morning dose)27. Capillary 
sampling can be performed by non-professionals but the sampling technique can affect the 
result, e.g. heavy pressure by squeezing the finger might increase the interstitial fluid in the 
sample, causing dilution. Collectors are instructed to wipe away the first drop of blood since 
this drop does most likely contain excess interstitial fluid34. Calibrators and quality controls 
(QC) samples for bioanalytical methods are usually prepared using venous blood taken in 
collection tubes containing anticoagulant, and thus differ from the patient capillary blood 
which is absorbed directly on filter paper.  
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2.2.3 The filter paper 
The filter paper used for collection of DBS is composed of a structured network of fibers 
made of polysaccharide cellulose with absorbent ability. The blood components, including 
the drugs, are bound by and incorporated in the polymers of the filter paper through hydrogen 
bonds when the paper dries. Small molecule drugs are usually stable in this dry matrix for 
long periods of time, typically up to several months depending on the drug and paper14. 
For TDM, untreated papers like Whatman 903 Protein Saver Card (GE Health care Ltd, 
Cardiff, UK) and Perkin Elmer 226 (formerly Ahlström 226, Perkin Elmer, Waltham,USA), 
have most often been used and both approved by the US Federal Drug Administration (FDA) 
as collection devices35,36. The papers are produced with strict quality control, following 
ISO9001 manufacturing standards. The choice of filter paper for patient sample collection in 
TDM analysis needs to be thoroughly considered. Factors that can influence the choice 
include method performance, price, commercial availability, traceability and adaptability to 
the laboratory workflow37. The work presented in this thesis was developed using Whatman 
903 paper. Apart from being quality assured according to clinical laboratory standards 
institute (CLSI ) requirements for mean serum uptake, mean blood absorption time and mean 
spot diameter by the manufacturer, the filter paper has also been thoroughly tested for 
variation in analytical results within- and between batches38. 
The dry matrix can increase stability of small drug molecules compared to blood or plasma in 
collection tubes. Increased stability has been shown for pro-drugs39, glucuronide metabolites 
and photosensitive drugs40,41. AEDs such as carbamazepine (CBZ), lamotrigine (LTG) and 
levetiracetam (VPA) have been found to be stable for at least 40 days at room temperature42.  
Blood tends to spread in a heterogeneous manner on the filter paper. This is a 
chromatographic effect, sometimes described as the `volcano´ effect43. Another effect 
describes the accumulation of solid particles at the outer edges of the bloodspot, causing a 
rim pattern, called the coffee stain effect44. Two processes have been described regarding 
spotting and spreading of blood on Whatman 903; how blood spreads on top of the substrate 
and how it spreads horizontal within the paper45. Comparisons have been made between 
different filter papers and the homogeneity of Whatman 903 paper was acceptable using 
autoradiography for visualization43. It was noted, however, that higher concentrations were 
measured in the edges of the spot for several investigated filter papers35,46,47. The 
chromatographic effect seems to be higher in blood with low Hct47,48. Variations in the 
homogeneity of DBS samples and the relationship between the chromatographic effect and 
Hct require thorough validation7,49. 
2.2.4 Effects of different hematocrit (Hct) and drop volume 
Blood with high Hct has higher viscosity which creates smaller spots on most filter papers 
and conversely a sample with low Hct spreads more on the paper, Figure 2. If a partial punch 
is taken from the DBS, a positive or negative bias on measured concentration will correlate to 
the Hct of the sample46,47,50–52. The effect of different Hct values has been identified as the 
 6 
most influential factor for quantitative DBS sampling methods with more than 15% bias in 
accuracy at extreme Hcts49,53. Hct effects can vary both with concentration and the type of 
analyte39,47. For some drugs, it has been reported that samples with high Hct values, >55%, 
had reduced recoveries54,55.  
 
Figure 2. Blood on filter paper with the same pipetted volume but different Hct from 0.25 L/L -0.60 L/L. Blood 
with low Hct and lower viscosity spreads more than blood with a high Hct. 
    
Hct values in children (6 months to 18 years) can vary between 0.30 to 0.49 L/L56. 
Development and validation of a bioanalytical method needs to at least cover the range of 
normal Hct values, 0.30-0.50 L/L50,57.  
 
Figure 3. A typical DBS sample from a child collected by the guardian. Collected blood drops have different 
volumes. The drop to the right is too small and irregular and can give rise to a negative bias due to the small 
volume.  
A filled circle in a Whatman 903 Protein Saver Card contains approximately 50 µL of blood. 
Blood drops with different volumes are expected during patient sample collection, Figure 3. 
The spread of the drop of blood on the paper can be affected by various factors. One effect of 
this is that a small drop usually has a negative bias and large drops have positive bias on the 
concentration ( although within ±10 % for relevant volumes)35. Blood drops with a very low 
volume also have a risk of not saturating the paper58. Despite of these possible contributing 
factors, the spread of blood on a Whatman 903 card has been shown to be linear and the area 
of the spot corresponds to a specific volume of blood that can be calculated59, Figure 4. 
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Figure 4. Blood pipetted at different volumes (n=3 for each volume) on a Whatman 903 paper. Area was 
measured by scanning the blood spots. There is a clear linear relationship between area (pixels) and volume. 
The area is somewhat affected by the hematocrit.  
Since drop volume and Hct affect the measured drug concentration when using DBS, 
accuracy and precision has to be measured in the validation process over the volume and Hct 
range expected to be present in the patient group to be studied. An important consideration in 
method development is the choice of Hct and volume for drops in the production of 
calibrators and QCs since they will function as a reference value35. 
In order to overcome the problems of unknown volumes and Hct effects, several solutions are 
now available in the form of automated devices, which can produce a spot with a defined 
blood volume. The whole spot can be analyzed instead of a partial punch and thereby the Hct 
effects are limited55,60–63. 
2.3 BIOANALYTICAL METHODS FOR QUANTIFICATION 
2.3.1 Immunochemical methods and LC-MS/MS methods 
The routine TDM laboratory relies on immunochemical methods for measuring the 
concentration of CBZ, LTG, LEV and VPA in plasma. These methods include, Cloned 
Enzyme Donor Immunoassay (CEDIA)64,65, Homogeneous Enzyme Immunoassay (HEIA),66 
and Quantitative Microsphere System (QMS)67. The assays differ in detection technique, but 
they are based on the principle of antibodies and conjugated drug. The drug molecules in a 
patient sample compete with the conjugated drug to occupy the free antibodies. Binding of 
the specific drug of interest is proportional or inversely proportional to the amount of drug 
present in the sample and is measured through absorbance change either by enzyme activity 
or turbidimetry (agglutination). Although immunochemical methods are highly sensitive, 
HCT35 y = 319x + 1037
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they suffer from cross- reactivity issues that cannot be fully controlled. The reagents and kits 
are produced by well-established manufacturers and sample volumes need to be high to 
ensure that the development of any given method on an immunochemical platform is 
profitable. Even though some immunoassays have been used for DBS as matrix68,69, it has not 
been the first choice of analytical platform when developing a DBS method70,71.  
The use of DBS methods for the quantitative measurement of drug levels was not common 
prior to early 2000 due to limitations in instrument sensitivity when measuring concentrations 
from small volumes (≤30 µL)72. The development of more sensitive LC-MS/MS instruments 
has been one of the strongest facilitators for making DBS possible as matrix for TDM7,72. The 
growing interest in using LC-MS/MS methods in the clinical laboratory is likely due to their 
increased selectivity over immunochemical methods and the possibility to simultaneously 
analyze several compounds in the same analytical run73. All the bioanalytical methods for 
DBS in this thesis were developed using LC-MS/MS73.  
In adsorption LC, the analytes are separated from each other through interactions with a 
stationary phase and a mobile phase. Depending on the polarity of the analyte and the mobile 
phase, more or less retention on the stationary phase is achieved. After passing the column, 
the mobile phase with the analytes is led into the electro spray ionization (ESI) interface. 
High voltages, temperatures and drying gas assist in the ionization of the analytes. In the 
mass spectrometer, the molecular ions are separated, followed by fragmentation. Selected 
fragments, unique for the analyte of interest, are measured in a detector. 
2.4 DBS IN THERAPEUTIC DRUG MONITORING (TDM) OF ANTIEPILEPTIC 
DRUGS (AED) 
Clinical perspective 
Over the last ten years, a multitude of bioanalytical DBS methods for different TDM analytes 
have been developed and validated 2. Unfortunately, few of these methods seem to have been 
established for the processing of real patient samples as an alternative to plasma or whole 
blood. One reason may be that there is a lack of bridging studies, ideally with patients 
performing self-sampling, as these studies require knowledge, time and money. Another 
contributing factor is that plasma samples have been traditionally used and are well 
established and relatively easy to implement for hospitals/laboratories. Even though some 
clinical validations on DBS have been performed on commonly used AEDs74–77, more 
clinical validations are needed to compare results obtained from plasma concentrations with 
capillary DBS samples gathered by patients at the clinic or at home14,78. 
For comparison of developed DBS methods for CBZ, LTG, LEV and VPA, see Table 1. 
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Table 1. Comparison of different DBS methods in humans, for CBZ, LTG, LEV and VPA 
Author and 
year 
Drug Internal 
standard 
Several
drugs 
Filter paper Analytical 
method 
Analytical 
range, µg/mL  
Extraction technique Punch size Collection 
by patients 
Type of 
blood 
Conversion 
factors 
Cross 
validation 
Abu Ruz et al  
(2010) 79 
LTG metformin No 
Whatman 
903 
HPLC-UV 0.5-20 
Extraction w ethylacetate:1M NaOH (24:1), 
3 min of vortexing, nitrogen dried and 
redissolved in mobilephase 
6 mm No 
10 µL 
venous 
No significant 
difference from 
plasma 
No 
Shah et al 
 (2013) 42 
CBZ      
LTG       
LEV 
hexobarbital Yes 
Whatman 
903 
Schleicher& 
Schuell 
HPLC-UV 
1-20 
1-20                
2-50 
Extraction w MeOH:MeCN (3:1), 15 min 
sonication, nitrogen dried and redissolved, 
SPE, nitrogene dried and redissolved in 
mobilephase 
6 mm No 
30 µL 
venous 
Not studied No 
Rhoden et al 
(2014)77 
VPA 
cyklohexane 
carboxylic acid 
No 
Whatman 
903 
GC-MS 5-250 
Extraction w MeOH:MeCN (3:1), 1 h 
sonication, extracts injected 
6 mm No 
50 µL 
venous 
1.883 
Yes         
n=17 
Kong et al 
 (2014) 74 
CBZ           
VPA 
5-p-
methylphenyl- 
5-phenylhy- 
dantoin  
Yes 
Whatman 
903 
GC-MS 
0.5-120 
0.5-120 
MeCN:NaOH 1M (24:1), 1 min vortex,  
5 min sonication,  nitrogen dried, 
derivatization, addition of heptane 
6 mm No 
30 µL 
venous 
1.95 (VPA)               
1.01 (CBZ) 
Yes 
n=182 
Pohanka et  
al (2014) 75 
VPA heptanoic acid No 
 Whatman 
903 
LC-MS 1.4-173 Extraction w MeOH, 60 min of agitation. 8-9 mm No 
20 µL 
venous 
DBS conc. 25% 
lower than 
plasma conc. 
Yes  
n=32  
 
Martins et al 
 (2014) 80  
CBZ propanolol Yes 
Whatman 
903 
HPLC-UV 
0.63-? Extraction MeCN:MeOH (1:3)during 30 min 
agitation. Evaporated and redissolved in 
mobile phase. 
8 mm No 20 µL  ~1  
Yes   
n=10   
Shokry et al 
 (2015) 76 
CBZ CBZE-d10 Yes 
Whatman 
903 
LC-MS/MS 1-40 
Extraction in MeOH:water:formic acid 
(80:20:0.1, v/v/v),orbital shaker for a period 
of 25 min at 37 ◦C. 96-well plate 
3.2 mm No 
20 µL 
venous or 
capillary? 
DBS conc. ~23-
30% higher 
than plasma 
Yes     
n=19 
Das et al  
(2017) 37 
CBZ nevirapine No 
Whatman 
cellulose filter 
paper 
HPLC-UV 2-20  
Extraction in MeOH/MeCN/H2O (1.5 ml+1.5 
mL+0.75 mL) for 15 min + 1 min vortexing 
Whole spot 
was used 
No 
20 µL 
venous 
DBS conc. ~20 
% higher than 
serum  
Yes 
n=80 
CBZ=carbamazepine DBS=dried blood spot LTG=lamotrigine LEV=levetiracetam  VPA=valproic acid, MeOH = methanol, NaOH = sodium hydroxide MeCN = acetonitrile 
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2.4.1 Antiepileptic drugs 
Around 50 million people in the world live with epilepsy, being the fourth most common 
neurological problem after migraine, stroke and Alzheimer´s disease81. The portion of the 
general population that have active epilepsy is somewhere between 4 and 14 per 1000 people, 
with the higher number referring to low- and middle-income countries82. In Sweden 
approximately 60 000 people have epilepsy and about 12 000 of these are children, 0 ̶ 18 
years old83. More than 70% of children and adults suffering from epilepsy can be successfully 
treated with AEDs which is the most common way to treat epilepsy. The treatment can either 
be life-long or prophylactic during several years.  
The goal of AED treatment is to control seizures with minimal adverse effects, preferably 
through drug monotherapy. Some AEDs are also increasingly used for the treatment of 
bipolar disorders, borderline personality disorder84,85 and neuropathic pain86. The chemical 
properties of the drugs covered in this thesis, CBZ, LTG, LEV and VPA are shown in Table 
2. 
Table 2. Chemical properties of four antiepileptic drugs 
Analyte Carbamazepine Lamotrigine Levetiracetam Valproic acid 
Molar mass (g/mol) 236.3  256.1 170.2 144.2 
Monoisotopic mass 
(g/mol) 
236.095 255.007 170.106 144.115 
Molecular formula C15H12N2O C9H7Cl2N5 C8H14N2O2 C8H16O2 
Structure 
 
 
 
  
pKa 13.9 pKa1 8.53  pKa2 9.21 
 
4.8 
 
Children with epilepsy can suffer from a wide range of syndromes, seizure types and 
underlying etiologies. TDM is essential for some AEDs and can be valuable in dose 
adjustments, particularly with drug combinations where drug-drug interactions are an issue. 
Some of the AEDs have complex intra- or inter-individual variations in pharmacokinetics, 
adverse effects and drug-drug interactions87. Children have higher plasma clearance of AEDs 
than adults and the clearance changes throughout childhood26. The complexity of epilepsy 
and the corresponding prophylactic treatment (especially in drug polytherapy) make TDM for 
AEDs an important tool for a better treatment outcome88 even though it has not been proven 
that TDM is an effective tool for all AEDs89.  
In 2017, a meta-analysis study was carried out with the purpose of finding the drugs with best 
evidence to be recommended for monotherapy of various forms of epilepsy90. CBZ, LTG and 
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LEV are all suitable first-line treatments for partial onset seizures. For individuals with 
generalized tonic-clonic seizures VPA is a first-line treatment but avoided if possible in 
women of reproductive age91 LTG and LEV can be used as alternatives. Essential 
information for each recommended drug studied in this thesis is presented in Table 326,87,92,93. 
Table 3. Pharmacology data for four antiepileptic drugs used to control epilepsy in children  
 CBZ LTG LEV VPA 
Year of approval 
in Sweden 
1965 1994 2000 1981 
Type of epilepsy 
most often 
treated with this 
drug 
focal seizures, secondary 
generalized seizures 
focal and generalized seizure in 
children w Lennox-Gastaut 
Syndrome, juvenile myoclonic 
epilepsy, infantile spasms, absence 
seizures, Rett syndrome 
idiopathic partial onset or 
generalized epilepsy,  
juvenile myoclonic epilepsy 
generalized epilepsies, focal 
seizures,  
Common 
adverse events 
drowsiness, nausea, dizziness, 
ataxia, hyponatremia 
dizziness, sedation, headache, 
ataxia, double vision 
somnolence, depression, 
behavioral abnormalities, 
headache, anorexia 
dizziness, weight gain, vomiting, 
tremor 
Serious adverse 
events 
skin rash, Stevens-Johnson 
syndrome, hepatic toxicity 
skin rash, Stevens-Johnson 
syndrome, toxic epidermal 
necrolysis, increased risk of suicide 
behavioral changes fatal hepatotoxicity, acute 
hemorrhagic pancreatitis, 
encephalopathy 
Maintenance 
dose: 
(children) 
10-20 (mg/kg/day) 1-10 (mg/kg/day)  10-20 (mg/kg/day) 
20-40(mg/kg) 
(2-3 times/day) 
Half-life (h) 10-13h (in children) 7-45h* (in children) 5-6h (in children) 8-13h (in children) 
Therapeutic 
range 
4-12 µg/mL (20-40µM) 2.5 -15 µg/mL (10-55 µM) 12-46 µg/mL (35-120µM) 50-100 µg/mL (350-700µM) 
Bioavailability 75-85% 98% >95% >90% 
Metbolism/ 
enzymes 
CYP3A4, CYP2C8 UGT1A4, UGT1A1, UGT2B7 
Only small amounts of 
hepatic metabolism 
Extensive complex liver metabolism. 
CYP and UGT enzymes involved. 
Main metabolite CBZ 10-11 epoxide^  2-N-glucuronide conjugate UCBL057  VPA-glucuronide 
Protein binding 
in plasma 
75% 56% 3% 74-93% 
Urinary 
extraction 
<1% ~10%  66% 1.8±2.4% 
Blood/Plasma 
ratioa 
0.95 to 1.05 1.1 to 1.3  0.51 to 0.70 
Drug-drug 
interactions 
including CBZ, 
LTG, LEV and 
VPA 
co-medication with VPA, risk of 
toxic levels due to increased 
CBZ epoxide. 
co-medication with VPA increase 
the levels of LTG, co-medication 
with CBZ reduce the levels of LTG 
CBZ and LTG enhance the 
metabolism and LEV 
concentrations can be 
reduced. 
CBZ and LTG give rise to enhanced 
elimination and plasma 
concentrations of VPA are 
decreased. 
a=ratios were experimentally derived from own experiments and are depending on the hematocrit level (see paper II) *=dependent 
on co-medication ^=active metabolite 
References for the Table:26,87,93,92 
There is a scarcity of bridging studies or cross-validations of DBS, including the AEDs in this 
thesis. DBS has been used for pharmacokinetic studies on CBZ (n=98) with blood from 
EDTA-tubes94. A study of adherence on five commonly prescribed AEDs was carried out 
with DBS samples collected at out-patient clinics and in some cases as self-sampling at 
home95. Incomplete sampling at home was mentioned as a problem. Other studies mostly 
developed methods for AEDs in proof of concept studies with few patient samples using 
venous blood collected in collection tubes. An overview of published DBS methods 
including, CBZ, LTG, LEV and VPA in humans is presented in Table 1. 
2.4.2 Blood to plasma ratio 
The distribution of drug concentration between the whole blood and plasma is referred to as 
the blood to plasma ratio. It is important to understand and study in relation to each drug 
before developing a DBS method27,96,97. DBS is in essence whole blood and the drug 
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concentration can be measured in whole blood instead of plasma as long as the unbound 
fraction of drug in plasma, the Hct and the partitioning are constant27.  
When the drug has a high affinity to plasma proteins, the partitioning into red blood cells is 
low and the blood to plasma ratio tends to be low ~0.55–0.60. VPA, is mainly distributed in 
plasma with a blood to plasma ratio of 0.6496 which leads to lower concentrations in whole 
blood (including DBS) than in plasma74,75,77.  
The distribution between whole blood and plasma for CBZ and LTG is nearly equal with 
blood to plasma ratios close to 1. Therefore, direct comparisons have been proposed for these 
drugs42,74,76,79,80. For LEV there are no earlier studies where the relationship between plasma 
and DBS concentrations in humans have been investigated. The fraction of drug in the red 
blood cells and the fraction of drug in plasma can be investigated by an in vitro assay98.  
2.4.3 Conversion approaches 
If a proportional bias between the drug concentration in plasma and the concentration in DBS 
is detected in the cross-validation, a conversion to an estimated plasma concentration can be 
calculated for the clinical interpretation71. Different approaches for this conversion are 
suggested in the literature. Theoretically, it should be possible to estimate a plasma 
concentration from the DBS concentration (𝐶𝐷𝐵𝑆) by taking the individual Hct and the drug´s 
fraction in red blood cells into account. Such an equation has been proposed98, where 𝑓𝐵𝐶  is 
the drug fraction in the red blood cells (Equation 1). 
𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 1.    
𝐶𝐷𝐵𝑆
(1 − 𝐻𝑐𝑡)
(1 − 𝑓𝐵𝐶) =  𝐸𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑 𝑝𝑙𝑎𝑠𝑚𝑎 𝑐𝑜𝑛𝑐.   
A similar approach was used to adjust DBS concentrations measured from VPA74. 
Another way of converting from DBS to estimated plasma is to use a mean ratio between 
plasma concentrations and DBS concentrations from a population and use this ratio as a 
factor (Equation 2). This approach requires data from clinical validations of many patients 
and awareness that extreme individual Hct can create bias. This conversion approach has 
previously been implemented for VPA77. 
𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 2𝑎.
∑ (
𝐶𝑝
𝐶𝐷𝐵𝑆̅̅ ̅̅ ̅̅ ̅̅
)
𝑛
⁄
= 𝑓𝑎𝑐𝑡𝑜𝑟 
𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 2𝑏.  𝐶𝐷𝐵𝑆 ∗ 𝑓𝑎𝑐𝑡𝑜𝑟 = 𝐸𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑 𝑝𝑙𝑎𝑠𝑚𝑎 𝑐𝑜𝑛𝑐. 
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2.5 DBS SELF-COLLECTION IN PATIENTS 
Patient perspective 
The use of DBS as a matrix opens the possibility of patient self-sampling at home. To our 
knowledge, DBS as alternative matrix for collection of samples at home for children with 
epilepsy has not been studied earlier. 
2.5.1 DBS collection 
Since collection of DBS has traditionally been performed by health care workers, DBS 
sampling guidelines have been developed 6,34. If these guidelines are followed by self-
sampling patients there is a good chance of quality in the collected sample.  
It has been shown that instructions are crucial to be able to collect an acceptable DBS 
sample99 and an effective way to instruct patients in practical techniques is the use of an 
instruction video100–102. Results have also shown that the participants wanted to have feed-
back on performance101.  
2.5.2 DBS and self-sampling at home 
Patient self-sampling has been performed successfully by different patient groups, for 
example in diabetes patients19,103. There are evaluated projects of self-sampling, although not 
with DBS, for international normalized ratio (INR) including self-sampling and 
monitoring104–106 as an example of patients willingness to be responsible for both sampling 
and monitoring. There are also examples from screening for hepatitis or HIV with DBS107,108.  
DBS in TDM has been used in different studies where the patient self-sampled at 
home20,109,110. The majority of the adult patients preferred capillary sampling at home over 
venous sampling. DBS self-sampling at home in a child population was reported as feasible 
in one study18. In-depth studies on how guardians can collect DBS from their children at 
home are lacking. 
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3 AIMS  
The general aims of this thesis were:  
 Investigate the feasibility of DBS as a matrix for measuring concentrations of AEDs. 
 Evaluate solutions for the use of DBS as a matrix in TDM of AEDs in children. 
 To investigate the perspectives of guardians and nurses on capillary blood self-
sampling of DBS.  
The specific aims were: 
Paper I: To study the matrix and to develop and validate an LC-MS/MS method for 
quantification of three common AEDs in DBS. 
Paper II: To compare capillary DBS concentrations with plasma concentrations of CBZ, 
LTG and VPA in a child population and evaluate different approaches for conversion to 
estimated plasma concentrations.  
Paper III: To develop and validate an LC-MS/MS method for four common AEDs, adapted 
to a clinical routine laboratory. 
Paper IV: To compare capillary DBS concentrations with plasma concentrations of CBZ, 
LTG, LEV and VPA in a child population and evaluate if DBS concentrations collected by 
guardians could be used for TDM of AEDs in the future.  
Paper V: Study how children with epilepsy and their guardians experience self-sampling of 
DBS and how their opinions and attitudes to self-sampling at home can assist to develop 
effective information and education for DBS self-sampling. Identify factors for successful 
DBS sampling.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  15 
4 METHODOLOGICAL CONSIDERATIONS 
This chapter presents the background behind the methods used in the work and how these 
methods were chosen based on laboratory tests and other decisions in the course of this work. 
Sharing the methodological considerations behind the different studies is a way to understand 
the importance of methods and how much influence these method decisions may have on the 
results. Method limitations are discussed to ensure impartial and critical evaluation of the 
results and findings in this thesis. 
Quantitative methods for bioanalysis have been combined with quantitative and qualitative 
methods related to patient opinions. Broad spectrums of research methods are covered to be 
able to achieve high quality data in the sampling-chain, from pre- to post-analysis. Even 
though a variety of methods are covered, the bioanalytical methods have been the main focus 
throughout this thesis. Although quantitative and qualitative methods focusing on the patient, 
provided valuable information, these methods are only partially described and not covered as 
thoroughly as they would have been in a thesis that had mainly focused on the patient’s 
perspective.  
Detailed information about materials and methods used in this work can be found in the 
material and method sections of the different papers, I-V. 
4.1 OVERVIEW OF STUDIES 
Method development and bioanalytical method validation have been the focus of this thesis. 
The designs for paper I and III are straightforward since they adhere to the guidelines for 
bioanalytical validation published by the European Medicines Agency (EMA)111. 
A level of complexity is added when patients and sample collections become part of the study 
design. In paper IV, data from two datasets were merged (including data from paper II) and 
the results were analyzed and presented together (Figure 5).  
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Overview of study IV. 
 
 
Figure 5. Overview of study IV. The study includes data from comparison of patient samples, DBS and plasma 
from paper II, dataset 1 (A). Dataset 2 (B) were samples collected by guardians (n=86) but also nurses (n=25) 
and these data were analyzed together with data from dataset 1 (D). A bioanalytical validation (E) was made 
and a clinical evaluation (F). (re-printed from paper IV with permission) 
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During the work with paper V, both quantitative (questionnaire) and qualitative (interviews) 
methods were used and the time period for this study was several years also including 
production of instruction material for sample collection (Figure 6). 
 
 
 
Figure 6. Timeline and overview of study V. 
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4.2  BIOANALYTICAL METHOD DEVELOPMENT 
Laboratory perspective 
Developing methods for measuring concentrations of different AEDs collected as DBS 
samples was new to the laboratory. The development can be described as an iterative process 
including the review of the scientific literature, discussions about the method, and decision-
making regarding the type of experimental progress. The goal was to develop rapid, selective, 
sensitive and robust methods that could be readily implemented in a clinical routine 
laboratory. 
4.2.1 Experiments during method development 
In the methods described in paper I and III, a part of the blood spot with a defined diameter 
was punched out with a hole puncher. In paper I, a small handheld hole puncher with a 
diameter of 3 mm was used (corresponding to ~ 3.2 µL blood). A handheld hole puncher 
requires strength and good technique to punch out discs and they cannot be punched directly 
into a vial or a 96-well plate (Figure 7).  
 
Figure 7. 1. Handheld hole puncher for 3mm filter paper discs from GE Healthcare. 2. DBS Wallac Puncher 
from Perkin Elmer with different punch sizes coupled to barcode reader and integrated with on-line laboratory 
information systems. Photo 2, courtesy of Perkin Elmer  
In the development phase for paper III an automatic puncher, capable of punching directly 
into a 96-well plate was used. The puncher was coupled to a barcode reader (for sample 
traceability) and was capable of producing larger punches of 4.7 mm (corresponding to ~ 7.8 
µL blood). A disc with a larger area has advantages since it contains more material and also 
to a greater extent equals out any inhomogeneity in the blood spot. By using a very small disc 
there is a risk of increasing the bias if the blood components are distributed unevenly on the 
paper7,46.  
In the development, paper I, different filter papers were examined. Whatman 903 A4 sheets, 
Whatman 903 Protein Saver Cards, Ahlström 226 and Whatman FTA DMPK-C cards, were 
used for measuring concentrations of spiked samples of CBZ, LTG and VPA. The goal was 
to find out if other filter papers were superior to Whatman 903 or if there were differences 
between the Whatman 903 A4 sheets and the Whatman 903 Protein Saver Cards, paper I. All 
the filter papers that were investigated consisted of untreated cotton linter papers (Whatman 
903 produced in a slightly more acidic environment than DMPK-C7). Since chemically 
treated papers, such as DMPK-B, may interfere with the LC-MS/MS detection due to ion 
suppression, untreated filter papers are normally preferred for the quantification of small 
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biomolecules (<900 Dalton) using LC-MS/MS14,38. The non cellulose-based Agilent Bond 
Elut paper for dried matrix spotting was also tested with promising results, but the blood 
drops were difficult to deposit on the surface and the manufacturer reported that it was 
unsuitable for use by patients112,113. 
The Whatman 903 A4 sheets were used for creating calibrators and QC samples for most of 
the development and validations, whereas the protein saver cards were used for collection and 
analysis of patient samples. The comparison between the different filter papers showed no 
significant difference (CV ≤5.6% and accuracy within ±6%, paper I) and the conclusion was 
that Whatman 903 sheets and protein saver cards could be used as proposed for method 
development and validation. 
Extraction of the analyte from the DBS is crucial and its efficiency can be evaluated by 
quantitative extraction recovery experiments usually carried out during method validation. 
For paper I and III different extraction solutions and techniques for extraction were 
investigated. Extraction with acetonitrile (MeCN) in combination with H2O or methanol 
(MeOH) resulted in lower peak areas for CBZ, LTG and VPA as compared to extraction with 
pure MeOH. The extraction with MeOH and 20% H2O (paper I) showed slightly higher peak 
areas for VPA. VPA is a weak acid that showed better ionization in negative mode than in 
positive and therefore was detected as negative molecular ion. Despite this, the sensitivity for 
VPA was not very good. It was concluded that the extraction was more effective for VPA 
when H2O was present in the extraction solution and therefore the optimization was done 
mostly to improve conditions for VPA. Improved recovery with water in the extraction 
solution for some analytes has been noted by others114,115. Weakened interactions between 
hydroxyl groups on the filter paper and the analyte has been suggested as an explanation to 
increased recovery/efficiency with the addition of H2O
116. When the method was further 
developed for paper III, with the inclusion of LEV, the water content in the extraction 
solution was increased to 35%.  
Ultra-sonication can increase the recovery at high Hct levels55,117. In paper I we reported 
recoveries of > 90 % and in paper III the process efficiency did not imply recovery problems. 
The liquid extraction with a step of gentle shaking was enough to extract efficiently. During 
method development extraction by ultra-sonication at normal and increased temperature was 
compared with normally extracted samples. The areas of the chromatographic peaks were not 
improved by sonication or heating. 
4.2.2  The liquid chromatography method 
LC-MS/MS methods can be simply understood as a separation step by chromatography and 
two separation steps and detection by mass spectrometry. The chromatographic method is 
more than just an inlet. By improving the chromatography it is possible to separate 
compounds in time and impurities in the matrix reducing the substantial matrix effects that 
would otherwise be a source of error for the mass spectrometry part of the system118.  
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In paper I, we optimized the chromatography by choosing a column and a mobile phase that 
best suited the three analytes (Table 4). In paper III the chromatography method had to be 
adapted to be suitable for the routine laboratory, which limited the numbers of columns and 
mobile phases that could be used. In paper I the total run time for the method was 4 minutes 
and adapting the method for routine application required shorter runtimes (Figure 8). In the 
end, the gradient program described in paper III was suitable for all four analytes and 
retention times were robust despite a shorter run time of 3 min. In paper III the method was 
adapted to be able to focus and separate LEV, a relatively polar compound. With a vacuum 
centrifuging step, the extracts were dried and reconstituted in mobile phase A, containing 
10% MeOH, which resulted in narrow peaks and stable retention times for LEV. 
Table 4. Comparison of methods, paper I and III 
Paper I III 
Filter paper Whatman 903 Whatman 903 
Punch (d in mm) 3 mm 4.7 mm 
Container Glass vial 96-well plate 
Extraction solution 200 µ of MeOH:H2O (80:20 v/v)  200 µ of MeOH:H2O (65:35 v/v) 
Extraction orbital shaker, 570 RPM, 5 min orbital shaker, 450 RPM, 30 min 
Reconstitution No mobile phase A:MeOH (90:10 v/v) 
Instrument Waters UPLC, Xevo TQ MS/MS Waters UPLC, Quattro Premier XE 
MS/MS 
Column Acquity UPLC BEH C18 
1.7µm, 2.1x100 mm 
Acquity UPLC BEH, C18 
 1.7 µm, 2.1 x 50 mm,  
Mobile phase A 2 mM ammonium acetate in H2O 10 mM ammonium formate, 0.15 % 
formic acid in H2O 
Mobile phase B 100% MeOH 100% MeOH 
Flow rate: mL/min 0.5 0.6 
Injection volume µL: 2 4 
Total run time: 4 min 3 min 
  
Figure 8. Visual graph of the gradient programs and retention times for the respective analytes in paper I and 
paper II. 
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4.2.3  The mass spectrometry method 
A key factor when developing reliable mass spectrometry methods is the availability of 
isotopically labelled internal standards (IS). The IS is added to the sample early in the 
extraction process to compensate for any losses during the extraction and also for variations 
in the ionization process in the mass spectrometer. In the collision cell the IS is expected to 
fragment in the same way as the analyte. For DBS samples, the most straight-forward and 
common sample preparation method is to add the IS to the extraction solution. In this case, 
the IS does not compensate for losses during extraction since it is not incorporated into the 
wet blood119. 
Internal standards used in the methods (paper I and III) were deuterated for CBZ, LEV and 
VPA (CBZ-d8 and d-10, LEV-d6, VPA-d6) and carbon-13-labeled for LTG (LTG-
13C3) , all of 
them stable internal standards that have similar retention time as their unlabeled 
counterparts120.  
During the tuning process, which aims to find the best precursor and fragment ions for each 
analyte, it was not possible to find stable fragment ions for VPA. Since the selectivity was not 
a problem, a possible solution for a TDM purposes was to let the precursor ion ([M-H]- m/z 
143) pass through the collision cell with just a small amount of collision energy to guide it 
through with minimal fragmentation. Another possible option was to derivatize VPA, but this 
process would have been more labor-intensive in the sample preparation step. As a result of 
the low abundance of VPA ions, VPA had a longer dwell time than the other analytes.  
Fine-tuning of the mass spectrometry parameters was done manually and compared to 
autotuning and the best options were used in the final methods. From the beginning more 
than one transition for each analyte was chosen. Before validation, however, the selection of 
transitions was narrowed down to the most suitable, usually the one with the most abundant 
fragment ion. Different injection volumes were tested and evaluated depending on calibration 
curves and their lower limit of quantification (LLOQ). The mass spectrometry settings of the 
two methods are summarized below (Table 5). 
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Table 5. Transitions and mass spectrometry settings, comparison paper I and III 
Paper Drug [M+H]+ [M-H]- Fragment CV CE DT 
I CBZ 237.2   178.9 32 34 0.030 
III CBZ 237.3   194.1 30 10 0.050 
I CBZ-D8 245.2   200.1 34 30 0.015 
III CBZ- D10 247.4   204.1 30 10 0.050 
I LTG 256.0   144.9 46 38 0.030 
III LTG 256.2   211.0 45 27 0.050 
I LTG-13C3 259.1   159.9 50 28 0.015 
III LTG13C3 259.2   214.0 50 27 0.050 
III LEV 171.1   153.9 15 7 0.050 
III LEV- D6 177.1   159.9 15 7 0.050 
I VPA  143.0  143.0 25 5 0.072 
III VPA   143.1  143.1 30 1 0.125 
I VPA-D6  149.1  149.1 25 5 0.015 
III VPA-D6   149.1  149.1 30 1 0.125 
 Settings Paper I Paper III 
Capillary voltage (kV) 1.50 1.50 
Source temperature (°C) 120 120 
Desolvation temperature (°C) 600 350 
Desolvation gas flow (N2) L/H 1000 800 
Collision gas flow (Ar) mL/min 0.15 0.15 
Ar=argon CE= collision energy CV= cone voltage DT= dwell time 
4.2.4  Limitations and strengths during method development 
In the method development for paper III, a limitation was the use of the same columns, 
mobile phases and wash solutions as used in the routine methods. One of the challenges was 
to solve different problems with the instruments, which require advanced skills. During this 
time period several different instruments were used and there were always small differences 
like tuning settings between instruments and day-to-day differences in instrument 
performance. An advantage is that in a routine clinical laboratory the staff always maintain 
the instruments in a structured and regular manner, thus minimizing the risks and reducing 
the possible bias that might occur if the maintenance was sub-optimal. Advanced technical 
and instrumental skills are crucial to be able to create a good LC-MS/MS method. 
4.3 BIOANALYTICAL VALIDATION 
In the effort to standardize bioanalytical method validation through the evaluation of various 
method parameters, EMA has published `Guidelines on bioanalytical method validation´ 111. 
The guidelines were followed in this thesis, with the addition of recommendations specific 
for DBS method validation121.  
Precision, accuracy, linearity, selectivity, carry-over, dilution integrity, matrix effect, stability 
and incurred sample reanalysis are all included in the full validation process according to 
EMA. Additional validation has been done for spot homogeneity, Hct effects, and stability in 
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extreme conditions, punch carry-over, reproducibility, effect of different spot volumes and 
capillary versus venous blood49,121,122. Validations were performed on two different 
instruments, with at least two biomedical scientists preparing the samples, during a prolonged 
period of time, thus making the validation process to mirror diverse conditions that are likely 
to occur in a routine laboratory over time.  
4.3.1 Calibrators and quality controls (QC) samples 
Fresh whole blood was used for creating calibrators and QC samples. Whole blood was 
gathered from volunteers and Hct was measured at the time of collection. In order to match 
the average Hct of 0.37 L/L found in the child population, blood was prepared to have an Hct 
of 0.40 L/L by adding or removing plasma after centrifugation50. Hct was measured once 
again before spiking and 0.40 ± 0.01 was accepted. Samples were always gently mixed on a 
rocker for more than 30 minutes before distributing the blood on the filter paper. 
In paper III the stock solutions were prepared in dimethyl sulfoxide instead of MeOH for 
CBZ and LTG. The risk of precipitation when spiking whole blood was lower with dimethyl 
sulfoxide than with MeOH and LTG was easier to dissolve in dimethyl sulfoxide. Solvent 
volumes never exceeded 5% of the total volume in the working calibrators or controls. Blood 
from different individuals were never pooled as Hct measured from pooled EDTA blood 
differed significantly from the expected mean when batches of blood were tested. The blood 
was pipetted onto filter paper A4 sheets with calibrated pipettes. 
4.3.2 Punch carry-over 
Carry-over from the hole puncher needs to be investigated since it is usually not cleaned 
between samples. Carry-over from the puncher can be reduced by punching white filter paper 
between every sample. The carry-over was assessed by punching a high concentration spiked 
sample followed by three times punching of blank filter paper. From these tests it was 
concluded that punches of blank paper between the samples were not necessary (paper I and 
III). 
4.3.3 Stability and extreme conditions 
The idea of including extreme conditions in the validation for DBS is that the samples must 
be robust against hot, humid or cold mailboxes and transportation conditions. QC samples as 
well as patient samples were put in incubators in 50°C for up to 48 hours or at -20°C.  
Analytes on filter paper can be hydrolyzed depending on humidity123 but it has been shown 
that DBS are no longer affected after a drying time of 2.5 to 3 hours at ambient 
temperature124. Samples were always stored in zip-lock bags with desiccant packages to 
prevent high humidity. Robustness to humidity was not tested in the validation for these 
methods but it has been reported that the homogeneity of Whatman 903 was not affected by 
humidity when assessed by quantitative autoradiography studies43 while others have shown 
effects of degradation in extreme humidity conditions125.  
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4.3.4 Bias of different Hct and spot volumes on the concentration 
Throughout the laboratory work, the impact on quantification by different Hct and spot 
volumes was extensively and repeatedly tested. In paper I different Hct levels between 0.20 
to 0.60 L/L were tested and different volumes from 15 to 50 µL. In paper III, Hct levels and 
different spot volumes were investigated in the same test. The idea was to study possible 
combined effects on the concentration when combining, for example a small volume with a 
low Hct.  
Patients being offered DBS self-sampling at home, should either have a normal Hct, or if in 
risk of being outside the normal range, a known Hct value so that he concentration bias can 
be corrected for.  
4.3.5 Recovery, matrix effects and process efficiency 
For LC-MS/MS methods it is important to evaluate if the sample matrix could introduce ion 
suppression or enhancement in the ion source. The analytes can compete with other co-
eluting molecules in complex series of charge-transfer and ion-transfer reactions126. 
Competition between molecules in the ion source may thus affect the intensity of the desired 
ions. Since this process is matrix-dependent the evaluation of matrix effects is done with 
unpooled blank matrix (blood) from six different individuals127, Figure 9. The six samples are 
spiked with low and high known concentrations of the analytes to create pre-extraction 
samples (A). Corresponding blank samples (same patients) are extracted according to the 
method and spiked to the same concentration used for the pre-extraction samples, thus 
producing post-extraction samples (B). The sets of pre- and post- extraction samples are then 
compared with neat solutions, of the same concentrations (C). The peak responses (area or 
intensity) are compared, and different ratios calculated to determine the extraction recovery 
(A/B ratio), matrix effects (B/C ratio) and process efficiency (A/C ratio), Figure 9.  
 
 Figure 9. Experimental set-up for measuring recovery, matrix effect and process efficiency.  
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This evaluation has been carried out in different ways during the various validation processes. 
In paper I, the method was simple and whole spots containing 10 µL of pipetted blood from 
six different individuals were used. The extraction solution was scaled up to correspond to the 
same ratio between blood and solution as in the method.  
In paper III, we decided to assess process efficiency exclusively (compare pre-spiked sample 
with neat solution). When only process efficiency is done (post-extraction samples not 
required), there might be a risk that ion enhancement can hide a low recovery. 
Post-column infusion experiments are not often reported in validations but can be of 
importance to reduce the risk of interfering substances, e.g. phospholipids that may suppress 
the analyte signal126. In the post column infusion experiment no dynamic matrix effects were 
identified at the retention times of the analytes, paper III, Supplementary 1. 
4.3.6 Capillary versus venous blood 
Even though capillary blood is used in DBS for self-sampling at home, venous blood was 
used to prepare calibrators and QC samples in the validation process. Comparison of capillary 
versus venous blood was covered in the validation. Since capillary blood is a mixture of 
venous and arterial blood and the collection sites are different from each other, it is possible 
for differences between venous and capillary blood concentrations to arise128. It has been 
proposed, however, that any differences in measured drug concentration are likely to be 
noticed only shortly after drug administration27. For TDM, the sampling is carried out as 
trough concentrations, several hours after the drugs were administered.  
Venous and capillary blood from three different individuals was each spiked at low and high 
concentration levels. Only small differences between spiked capillary and venous blood 
(precision and accuracy <10%) were seen for the four AEDs. This finding made it possible to 
use spiked venous blood for calibrators and QC samples instead of capillary blood. 
Comparison of Hct between capillary blood and venous blood has not shown significant 
differences although greater variance between repeated sampling of capillary samples was 
found129.  
4.4 METHODS FOR COMPARISON BETWEEN PLASMA AND DBS 
CONCENTRATIONS 
Laboratory and clinical perspective 
The aim with the comparison of two methods would logically be to evaluate if they show the 
same results and can be used interchangeably. The comparison of DBS and plasma 
concentrations include a comparison between different matrices and different bioanalytical 
methods. It is likely that concentrations in one matrix differ from the other due to the blood to 
plasma ratio, and a factor can be applied to correct for this difference. There will be some 
variation in the factor and as the sample size increases, the confidence interval will be 
smaller. As described earlier, patient Hct can also have an influence on the result and to some 
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degree contribute to variation. In the end the most important thing to consider is if these 
variations might affect how the TDM answers for AEDs are used in practice 
Several proposed limits for acceptance of method differences exist. The Australian Royal 
College of Pathologists, (RCPA) propose limits for most AEDs at ± 10% within the 
therapeutic range. Limits for cross-validation from EMA are wider. The difference between 
the two values obtained should be within 20% of the mean for at least 67% of the repeats. 
EMA limits were considered to be suitable for these comparisons in a first step of clinical 
validation while the therapeutic ranges for CBZ, LTG, LEV and VPA are wide. It is 
recommended to use limits building on what is accepted in relation to how TDM is used for 
the specific drug. This approach was adhered to by performing a clinical evaluation after the 
clinical validation.  
  
In this thesis, the approach has been to perform first a bioanalytical clinical validation and 
second a clinical evaluation. An accepted bioanalytical validation might still give rise to 
concerns; is the method good enough? To evaluate this, clinicians were involved to interpret 
if the variations between the concentration results should have generated the same 
recommendations. For the included AEDs, this was done by defining scenario categories for 
result classification 
1. In a patient with poor effect, is there room for dose escalation?  
2. In a patient with suspected adverse effects, is there room for dose reduction?  
3. Is the concentration too high (potential of serious adverse effects)?  
As long as the variations did not result in different outcomes in relation to these categories, 
they were judged to be acceptable. After the clinical evaluation, it was possible to decide 
whether the methods could be used and were valuable in TDM of AEDs for children with 
epilepsy. 
4.4.1 Regression models 
Methods for comparing measured concentrations from different matrices must be chosen. 
One of the most established methods for comparison between plasma concentrations and 
DBS is the Passing-Bablok regression130,131, a non-parametric model insensitive to values 
from outliers. Constant and proportional bias can be estimated and analysis for linearity 
indicates significant difference from linearity.  
The Passing-Bablok regression was used for comparison both in paper II and IV. In paper IV 
the interpretation was much less straightforward. In paper IV, the decision was to use simple 
linear regression and Pearson’s correlation coefficient for presentation. Since the Pearson´s 
correlation only describes the linear relationship and not the agreement between data sets, 
Lin´s concordance correlation coefficient132 test was also applied.  
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4.4.2 Difference plots 
Bland-Altman plots are comprehensive and extensively used for visual presentation of the 
differences between measurements133. The plots were used to study differences, distribution, 
tendencies and outliers in the compared datasets. Since CBZ and VPA need conversion 
before concentrations can be compared, the converted DBS (CBZ, VPA) concentrations were 
presented in the comparisons. The Bland-Altman plots can be used either with absolute or 
relative values on the y-axis. Since the presentation with difference in concentrations on the 
y-axis is most often used, we decided to use that presentation and to add limits of ± 20% to be 
able to estimate the % bias in different concentration ranges in Figure 3, paper IV. 
4.4.3 Conversion with Hct and K-value versus ratio approach 
If the DBS concentrations differ proportionally to the plasma concentrations, it is possible to 
adjust the DBS concentrations to estimated plasma concentrations. An alternative to DBS 
estimated plasma concentrations from DBS would be to construct therapeutic ranges and 
decision limits for uncorrected DBS data instead of taking the detour over plasma 
concentrations. This approach calls for much more DBS data than is present at this stage as 
the power of clinical data from plasma over DBS is indisputable.  
One method to create an estimated plasma concentration from a DBS concentration that was 
used in paper II was to include a K-value (the partitioning of drug into the red blood cells 
divided with the partitioning of drug into plasma) for the specific analyte and the individual 
Hct. This method for conversion was earlier used for VPA74. The methodological 
considerations are that individual Hcts and the K-value for each analyte must be available for 
this method of conversion and both of these parameters can be complicated to control, see 
section 2.4.2 and 2.4.3. The blood to plasma ratios for CBZ, LTG and VPA were investigated 
over the therapeutic concentration ranges and different Hct ranges in paper II 
(Supplementary). Blood to plasma ratios of the analytes were difficult to find in the literature 
and the idea was to investigate if there was a change in the ratio with different Hct and 
concentrations. Since the results showed that blood to plasma ratio varied, especially for 
VPA, it was difficult to use an equation for conversion with one average K-value (paper II).  
Another way of conversion is to use the average ratio between the plasma concentrations and 
the DBS concentrations and multiply the DBS concentration with this conversion factor, see 
section 2.4.3. The advantage is that it is straightforward, but the disadvantage is that the 
conversion factor is easily affected by outliers if the population is small.  
4.4.4 Limitations in the comparison 
Results from the comparison between DBS concentrations and plasma concentrations were 
gathered and generated during an extended period of time. The risk of large differences 
increases with longer storage periods, different instruments in use, new reagents, kits and 
batches for the immunochemistry analysis (routine plasma samples) as well as the use of two 
different instruments and methods for the DBS concentrations.  
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Another limitation in the design was that the collected routine plasma capillary samples were 
stored for only two weeks. One possible explanation for some of the large differences in the 
comparison study (paper IV) might have been caused by erroneous answers from the routine 
plasma concentration. Since the DBS samples were analyzed at a time point when the routine 
samples were already discarded (more than two weeks after collection), there was no 
possibility to re-run the plasma samples if the results from the comparison differed more than 
expected. 
It was difficult to collect enough patient samples for a clinical validation. At least 40 samples 
for comparison is recommended and this was especially difficult for CBZ134. During this time 
period it seems as other AEDs, such as LEV or oxcarbazepine, has been increasingly 
prescribed rather than CBZ135. 
4.5 MIXED METHOD 
Patient perspective  
For paper V, the choice of a mixed method design was decided in the analysis phase of the 
questionnaire data. The questionnaire gave information mainly on to what extent the 
guardians were satisfied with the instruction, the performance and if they were interested in 
self-sampling. The open questions were filled out by few guardians, contributing mainly with 
short positive sentences about the sampling procedure. In discussions with nurses at the 
neuropediatric clinics it was clear that the guardians had more experiences and opinions about 
this process than they wrote in the questionnaire. To be able to investigate the research 
question from different perspectives and to get a deeper understanding, one option was to 
make additional semi-structured interviews with informants that could contribute with rich 
and diverse information136,137. Such information has a greater potential to find problems and 
add value to patient education for DBS sampling, than the descriptive information from the 
questionnaire. 
A mixed-method sequential explanatory design138 was an approach that was suitable, because 
answers from the questionnaire could not be fully understood. One example was that ~70% 
had answered that it was easy to execute the DBS collection at the clinic but >80% thought it 
would be easy to collect at home (Supplementary 1, paper V). Why did the guardians think it 
would be even easier to collect the DBS in the home environment? Many guardians (~60%) 
thought it was somewhat painful for their child, but they still seem to be attracted to perform 
self-sampling at home if possible. Interviews as a collection method had the potential to 
answer these questions. Mixed-method sequential designs are most often designed with a 
main focus on the quantitative part of the study139. We decided to give equal importance of 
the quantitative and the qualitative part. 
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4.5.1 Study subjects and data collection, paper V 
Questionnaire 
Inclusion criteria for the questionnaire were the same as for participating in the DBS 
comparison project (paper IV). Nurses were requested to ask patients (children with epilepsy 
and their guardians) when they were scheduled to collect a blood sample for measuring AED 
concentration. On this occasion the nurses asked if the family was interested in participating 
in the study. Families that showed an interest in future self-sampling at home and understood 
Swedish, received written and verbal information. All guardians and participants ≥12years 
signed a written consent. Children under 12 were informed by nurses and guardians and if a 
child refused or if there was a sign of unwillingness to cooperate, the self-collection was not 
carried out. The questionnaire was handed out together with the blood collection kit and filled 
out by guardians or older children who had sampled themselves, immediately after the DBS 
blood collection. 
Interviews 
Two interview guides, were developed in the study, one for guardians and one for nurses. In a 
first phase research questions were defined and areas of interest related to the question, were 
created in the interview guide. The guide with questions were tested on nurses and one 
guardian in the development phase. Five main areas, related to experiences and feelings that 
informants had during the sample situation, were covered in the interview guide. 1) the 
education 2) feelings before the blood sampling collection 3) the sampling and the blood 
collection 4) the communication and relation between child and guardian. A fifth area, not 
related to the actual sampling procedure, considered the participant’s thoughts about the 
future and performing home sampling. The interview guide for the nurses covered the same 
main areas, except number 2, but also how the nurses evaluated their own role in this 
situation. A total of nine interviews were performed and analyzed (seven guardians and two 
nurses, purposively chosen by the author and a research nurse in the team) . 
Since all the guardians included for interviews had performed the sampling themselves, all 
had experiences and feelings related to the questions. The included nurses had experiences 
from being educators in the self-sampling situation and they had valuable information and an 
overview perspective since they had seen many guardians collect DBS samples.  
The informants were encouraged to give detailed and rich descriptions. The interviewer used 
different kinds of tools to make the informants share their experiences and feelings, for 
example warm-up questions, follow-up questions where the guardians were asked to 
exemplify, clarifying questions and closing questions with a summary to seek agreement in 
what was said. The interviews ended when a sense was achieved that the whole picture was 
addressed140. 
In qualitative research the term “saturation” is often mentioned in relation to sample size and 
is referring to a whole methodology141. In the work with the qualitative method used in paper 
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V, interviews were performed and analyzed in a process. When no more categories emerged 
from the data, two additional interviews were performed and after this saturation was 
assumed. Another model to guide the judgement of sample size in qualitative research has 
been proposed142. The model is called “Information Power” and takes into consideration 
several items and dimensions that can increase the information power, which means that 
smaller sample is needed. For example, a narrow aim of the study, if the participants hold 
characteristics highly specific for the study, an established theoretical background, high 
quality of the interview dialogue (interviewer experience) and analysis strategy (case versus 
cross-case) are items that can increase the information power. This model was discussed in 
relation to sample size during the work with paper V. 
The transcribed interviews were handled as confidential material and should not be able to 
reveal the identity of an informant. Participants’ lists, audio recordings, questionnaires and 
transcribed interviews are kept in a locker so that no one without permission can get access to 
the data. Participants were informed of their rights to withdraw without an explanation at any 
time during the study period and that their decision of participation or not, would not affect 
their treatment.  
4.5.2 Methods for analysis of quantitative and qualitative data  
Questionnaire 
The primary focus of the questionnaire was to give feed-back on the given information, 
(practical from nurse and the video instruction), of the blood collection process and to 
estimate the preference of self-sampling at home. The questionnaire was developed by the 
research group and iterated between nurses, pediatricians and researchers before finalized.  
The aim was to use descriptive analysis mainly to get feed-back from the guardians and use 
the information to improve the instruction video and the education situation. From the 
beginning there was no intention to analyze correlation between for example age of the child, 
and successful sampling or preference for self-sampling at home. In the analysis phase some 
of the questions were investigated in relation to the age of the child with Fisher´s exact test. 
The idea behind this was that it was interesting to understand if it was more complicated to 
collect samples from smaller children than older and therefore two age groups were formed, 
≤4 or >4 years old.  
Interviews 
Thematic analysis was chosen as a method for organizing and interpreting data from the 
interviews. This method to analyze the data has a tradition in health services research and has 
been used to find diverse perspectives of studied phenomena143,144. In paper V the analysis 
process has been inspired by Malterud and systemic text condensation144. The method is 
structured with guiding steps and said to be suitable for nurse students or others with limited 
earlier experience from analyzing qualitative data144. Thematic analysis is also a method that 
give accessibility and flexibility and a suitable entry to qualitative research for beginners143. 
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The analysis phase is an ongoing and iterative process where the researchers are immersed in 
the data. The process also means repeatedly moving between different stages in the data. This 
requires structure and organization of the different stages in the process. In the analysis for 
paper V the data and the different steps were iterated, organized, structured and documented 
through the whole process. 
4.5.3 Limitations (mixed-method study) 
The questionnaire, quantitative method 
The number of families that were asked to participate in the study (questionnaire) was not 
registered. It is therefore unknown how many of the families who were asked for 
participation and how many that declined. There is a risk of bias, for example that the data 
about the guardians’ education level or socio-economic background was not collected can 
create selection bias and the studied group may be different from the rest of the guardians 
interested in performing self-sampling at home.  
Another limitation was that it was difficult to find information on the total numbers of 
children/families listed at the two neuropediatric clinics that were involved in the study. To 
get an estimation of how many patients were included, we compared it with the number of 
prescriptions of the four AEDs (0-19 years old) that were registered as collected at the 
pharmacy in Stockholm Health Care Region (SR) in 2016 by the national drug prescription 
register 135. From this register it was found that 72 patients correspond roughly to 3.5% of the 
total patients (0-19 years old) treated with these AEDs (SR). Since >15% children were on 
drug polytherapy it means that the study population represents more than 3.5% of the 
possible patients in SR in this age group. The four AEDs covered 92% of all the AED 
prescriptions in SR. 
The children and their guardians were from two major university hospitals in the SR region 
and therefore the pediatricians might have more access to research than other Swedish 
regions. On the other hand, there are national recommendations by the Swedish Medical 
Products Agency on how to treat children with epilepsy and all should be treated by and in 
contact with specialized children neurologists and AEDs are recommended according to 
guidelines. The study design was limited to the Stockholm Health Care Region and to include 
other regions in Sweden would have strengthened the transferability. 
The initial aim was to analyze the questionnaire with descriptive statistics, but it would have 
been interesting to also find out if there was correlation between for example problematic 
sampling related to concomitant diagnose and/or age. This aspect was not thought upon from 
the beginning and it was therefore difficult to analyze the questionnaire in relation to 
correlation hypothesis. Demographic data like age, sex and education level of the guardian 
and concomitant diagnose in the child was not collected and this information could have been 
valuable to be able to find interesting correlations in the material.  
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The interviews, qualitative method  
Qualitative methods should be discussed in terms of data quality and validity, to ensure 
trustworthiness of the results145. During the process where meaning-units, codes, sub-
categories and categories were formed, two researchers were involved. To increase validity, 
another independent research nurse analyzed the material. Furthermore, the members of the 
research group read the transcripts and confirmed that the results were rooted in the original 
transcripts. The citations used were another way of adding validity in analysis of the 
categories, paper V.  
In qualitative research methods, credibility is important to create trustworthiness. The concept 
of credibility refers to the ability and effort of the researcher reflexivity, i.e. how much the 
researcher explains about her background and experiences and how this may affect the 
research, the ability to question the findings and interpretations and thinking about context 
and bias136. The principal researcher/author of this thesis, who also performed the interviews 
had a previous understanding from earlier experiences and contacts mainly with the nurses 
involved in the study and the sampling procedure but also from analyzing the questionnaires. 
Although it is difficult to bracket the preconceptions that resulted from these contacts, the 
researcher was conscious about her earlier experiences and that they may have influenced her 
opinion about the sampling situation. The author had no earlier experience from qualitative 
research but worked with an experienced qualitative researcher through all parts of the work.  
The first interview had a face-to-face format with one guardian and was used as a pilot 
interview for the interview guide, and since the data qualified for answering the research 
question it was used in the analysis. The informants thereafter had the possibility to choose 
what best suited them and all the guardians chose telephone interviews for different reasons. 
The interviews with the nurses were face-to-face. There are advantages and disadvantages 
with these interviewing methods140,146. In a face-to -face interview it is easier to catch up on 
interesting things behind the words because it is possible to see and analyze facial 
expressions. On the other hand, it is important that the informants feel comfortable and free 
with a high degree of influence over the interview situation147. The telephone interview was a 
way of making the data collection easier to deliver for the informants.  
Having had five mothers and only one father participating in the study (paper V) is seen as a 
limitation. The aim was to have a situation that was resembling the ratio between mothers and 
fathers who come to the clinics with their children. At least 40% of fathers as guardians 
would have been satisfactory. At the time of the interviews however, it was difficult to find 
available fathers.  
How transferable are the findings in paper V136? The results can be of value in other areas in 
health care when blood samples from children could be collected in a home environment. The 
information from the study can be used to prepare parents, children and nurses and to produce 
effective instruction material for DBS sampling in a home environment.  
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5 ETHICAL CONSIDERATIONS 
The principles of the Declaration of Helsinki148, applicable to the research that has been 
conducted throughout this thesis, is briefly commented upon in this section.  
Risks, burdens and benefits 
In the study (II, IV and V) where children and guardians were asked to participate in DBS 
collection, burdens and risks, although small, have to be considered. For a couple of children, 
an extra fingerprick was necessary to complete the collection for both routine and -DBS 
collection. However, the design of the blood collection was done to avoid this by using the 
same fingerprick for both samplings. The children had to be still for blood collection during 
longer time than for routine capillary sampling, which can be demanding. For guardians, 
there was a risk of burden because they may feel that they harm their children by performing 
the fingerprick. The use of spring-loaded lancets makes it possible for unexperienced persons 
to fingerprick without risks. The risks and burdens for the individuals are considered to be 
small and have to be related to the benefits that may come with the research for this particular 
group, the possibility of performing self-sampling at home instead of collecting the sample at 
the clinic at the hospital. All individuals participated voluntarily and had the right to 
withdraw from the study at every moment. Information about the risks and procedures for 
blood collection was thoroughly described, both in written and verbal information.  
 
Vulnerable groups and individuals 
In the declaration of Helsinki, it says that research with a vulnerable group is only justified if 
the research is responsive to the health needs or priorities of this group and the research 
cannot be carried out in a non-vulnerable group. This study was made on a vulnerable group, 
children with epilepsy. One might ask why this research had to be carried out in this specific 
group? To use an adult population for the study had been possible if the research question had 
been limited to investigation of the matrix and its comparison to plasma. The drive behind 
this research has been from the perspective of these children and their families together with 
interest from the pediatricians. To find obstacles and to prepare this specific group for self-
sampling at home could not have been done in an adult group.  
 
Informed consent 
All guardians and children ≥12 years old signed a written consent that was included in the 
ethical application. Effort was taken to have informed consent149,150 from all children and 
guardians, meaning that the nurses involved in the study tried to inform the children in a way 
that they could understand. If a situation evolved with signs of misunderstanding or 
unwillingness from the child, the nurse recommended the guardian to not perform the 
fingerprick.  
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6 RESULTS AND DISCUSSION 
In this section some of the most important results from the studies, paper I-V, are presented 
and discussed in relation to what can be confirmed or opposed from the literature. Reasoning 
of findings coupled to the initial aims is presented as to conclude and highlight what was new 
in this research and to what extent the findings will contribute to practice or future research.  
Laboratory perspective 
6.1 METHOD DEVELOPMENT AND VALIDATION 
Throughout the work with this thesis, standard validation parameters as well as additional 
parameters specific for DBS were repeatedly investigated for CBZ, LTG, LEV and VPA on 
Whatman 903 filter paper. 
Accuracy and precision were within ± 15 and ≤ 15% (LLOQ ± 20 and ≤ 20%)111 for both 
methods developed in paper I and paper III, with slightly better results for precision in paper 
III than paper I. The therapeutic ranges for the AEDs were well within the quantification 
range of the analytical platform, Table 6. The methods were adapted to the conditions of the 
routine TDM laboratory, in relation to choice of columns, mobile phases and short runtimes, 
and the methods showed robustness and good accuracy and precision. Several full validations 
of the methods were undertaken during this time and results were repeatable. 
Table 6. Method parameters of plasma analysis and DBS analysis, paper I and III 
CBZ=carbamazepine, LTG=lamotrigine, LEV=levetiracetam, VPA=valproic acid 
Drug Matrix Platform Quantification 
range µg/mL 
Therapeutic 
range µg/mL 
Precision (%) Calibration 
 Within Between  
CBZ Plasma CEDIA 1.18-19.8 4-12 1.2-5.2 4.1-5.2  
CBZ DBS LC-MS/MS PI: 0.75-40    
PIII: 0.59-18.9 
 1.6-5.1  
4.8-6.0 
3.1-15.3 
4.8-7.5 
Quadratic 
Linear 
LTG Plasma QMS 1.28-12.8 2.5-15 3.1-9.2 4.5-13.9  
LTG DBS LC-MS/MS PI: 0.75-40    
PIII: 0.64-20.5 
 2.4 -11.7 
4.4 -10.5 
4.8-10.6 
4.8-7.2 
Linear 
Linear 
LEV Plasma HEIA 2.04-100 12-46 4.2 -15.5 6.2-13.7  
LEV DBS LC-MS/MS PIII: 0.83-67.7  5.5-7.8 4.9-8.5 Quadratic 
VPA^ Plasma LC-MS 14.4-225 50-100 1.5-2.7 1.5-4.8  
VPA* Plasma CEDIA 14.4-150  0.7-1.6 1.1-1.9  
VPA DBS LC-MS/MS PI: 5-300 
PIII: 2.90-145 
 2.7-7.5 
5.4-9.7 
4.7-11.8 
4.5-8.8 
Linear 
Linear 
^=the plasma method used for comparison in paper II *=the plasma method used for comparison in paper IV, 
PI=paper I , PIII=paper III 
We thoroughly investigated the effects of different Hct and drop volumes to enable the study 
of the combined effects. Results showed a trend of negative bias with small drops and low 
Hct and positive bias with large drops and high Hct (see Figure 10).  
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Figure 10. Combined bias (%) from Hct and volume on measured concentrations (modified from paper III, 
Supplementary information with permission).  
This bias on the concentration was expected when using Whatman 903 filter paper in 
combination with punching a fixed diameter, see section 2.2.4 and 4.2.1.  
In paper I, Hct levels and different drop volumes were examined separately. The results 
showed bias within ±10% for different volumes (15 ̶ 50 µL) and within ±15% for Hct levels 
between 0.35–0.60 L/L. There was no additional effect noticed when Hct levels and volumes 
were combined, as performed in paper III. A bias greater than -15% was seen for LQC VPA 
at low Hct (0.30 L/L), Figure 10. On the other hand, this low concentration (LQC was 60 µM 
or 8.7 µg/mL) is below the lower therapeutic range for VPA and is therefore unlikely in 
patient samples. The approach of combination of different volumes and Hct in the same 
validation assay has not been applied in other published articles. Often the parameters are 
investigated one by one and additional or nullifying effects cannot be studied. Although, there 
are articles showing combined effects of Hct, concentration and recovery151,152. 
The method was validated for patient samples with drop volumes ranging between 15–50 µL 
in a Hct range of 0.35–0.50 L/L. The same results, with minor influence of different volumes 
but more for extreme Hct, has been identified by others42,76,77. No patient was excluded due to 
extreme Hct, paper II. In paper IV Hct values were not collected since the assumption was 
that no patients in the study would have extreme Hcts.  
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One might think that large differences between results in DBS (converted for CBZ and VPA) 
and plasma can be explained by very low or high Hct values in some patients and that the 
difference could be corrected with adjusted Hct. However, a correction for Hct in the patient 
samples only changed the results of the DBS concentrations with an average of 2.1% (paper 
II, Supplementary 7). Hct correction was not contributing to better agreement between 
methods and individual Hct values could not be used as an explanation for large differences 
in some of the sample pairs. On the other hand the individual Hcts in this population did not 
vary much and were all in the range of 0.32 ̶ 0.42 L/L. A recent clinical validation of DBS for 
sirolimus and everolimus found that large differences in some of the samples could not be 
explained by the patient Hct153. Since the bias of extreme Hct can be large, it must never be 
neglected that extreme Hcts will affect the measured concentration on Whatman 903 filter 
paper and these types of bias must be avoided. 
The correlation between differences in volumes of blood drops was also studied. Small or 
large drops of blood (volumes) in the patient samples did not explain any large differences 
between DBS and plasma results. When the concentration was measured in two different 
blood spots from a patient sample the mean CV% between spots was 3.2 (CBZ), 4.0 (LTG), 
3.1 (LEV) and 3.9 (VPA), Supplementary 1, paper IV. Despite the different blood volumes 
deposited on the filter paper, the CV% was small. 
When comparing peripheral to central punches, the peripheral punches had higher 
concentrations than the central with a mean bias of 8.2 ̶ 11.0 % higher concentrations in the 
peripheral spots for the different AEDs, paper I, Table 7. This inhomogeneity on Whatman 
903 paper has also been reported for other DBS methods and analytes with essentially the 
same results46,47,51,154. The result of inhomogeneity in the spots is considerable and 
emphasizes that it is important to always sample the same location within the spot to prevent 
additional bias. As long as a central punch from the filter paper is used, it is possible to limit 
the bias from the chromatographic effect. Whole spot analysis would be more representative 
of the blood sample155 but is not possible with collection of blood from fingerpricks on 
Whatman 903 filter papers when the volume of the drops is unknown. 
Results showed that CBZ, LTG, LEV and VPA were stable in DBS at room temperature for 
up to one year, Table 5, paper III. No other studies have shown results for such long storage 
periods of DBS at room temperature for these drugs. Precision and accuracy were acceptable 
following storage at temperatures as high as 50°C and as low as -20°C. The results 
demonstrated that DBS is a robust matrix for these analytes and can resist harsh conditions 
since no trends were noted for any of the analytes and the accuracy was within ±15%, with 
only LTG HQC having +15.6% deviation from the nominal concentration after storage at 
50°C (in Table 5, paper III). We could thus show that patient samples can be transported in 
envelopes and stored in mailboxes for several days with a low risk of affecting sample 
quality.  
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The stability of LEV in fresh whole blood is affected by enzymatic degradation during 
storage in whole blood before separation of plasma156. Thus, it would be interesting to 
investigate if DBS may be a better choice than plasma when analyzing LEV  
Recovery and matrix effects have been studied in paper I and III, both in qualitative (post-
column infusion) and quantitative experiments. Results showed no dynamic matrix effects at 
the expected retention times of the analytes.  
In the validation for paper I, recoveries were between 93.6  ̶ 104.9% and matrix effects were 
within 98.7–116.3%, CV% 1.5–4.1 for all analytes (Table 4, paper II). Impaired recoveries 
have been noted with high Hct samples by others55,152 but in the investigation for paper I, we 
found that the high recoveries for CBZ, LTG and VPA were maintained also at high Hct, 
(0.60 L/L). In Table 4, paper III, process efficiency was between 90.1 ̶̶  96.4% (CV% 2.6  ̶  
4.4%), indicating high recoveries and low matrix effects. 
In conclusion, rapid and robust LC-MS/MS methods for measuring the concentration of 
CBZ, LTG, LEV and VPA in DBS have been developed with precision and accuracy that 
were in the same ranges as the routine methods. The methods were accepted according to the 
criteria for method validation from EMA, when performed in a normal Hct range. 
6.2 BRIDGING STUDIES AND STATISTICAL TESTS FOR AGREEMENT 
Clinical and Laboratory perspective 
Bridging studies for DBS and plasma were performed to evaluate if the methods could be 
used interchangeably157.  
In paper II and IV, Passing-Bablok tests showed a clear proportional bias for VPA, which 
indicated a need for conversion into estimated plasma concentrations. For CBZ, the Passing-
Bablok tests did not indicate a need for conversion since the confidence interval of the slope 
included 1. Measured concentrations of CBZ in DBS, however, were constantly higher than 
those measured in plasma (paper II and IV). The conclusion was that DBS CBZ 
concentrations would be in better agreement with plasma concentrations after conversion.  
6.2.1 Conversion factors 
After investigating different conversion approaches (paper II), the conclusion was to use the 
ratio approach, where a factor was calculated from the average DBS and plasma 
concentration ratios. The factor for CBZ was 0.84 in paper II and 0.85 (standard deviation 
0.10 for both) for the pooled dataset in paper IV. In other DBS plasma cross-validations for 
CBZ, higher DBS than plasma concentrations were reported in line with our results37,76 . 
Other groups found no difference between the matrices for CBZ74,80, Table 1. None of these 
cross-validations were comparisons between capillary fingerprick blood and plasma but were 
based on venous DBS. In paper II and IV all data presented is from capillary blood samples 
from a fingerprick directly deposited on the filter paper, which is the true matrix to be studied 
in a clinical validation for DBS. 
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The choice of a correct factor for conversion was more challenging for VPA since the factor 
varied from 1.58 (standard deviation, 0.16) in paper II to 1.64 (standard deviation 0.20) in the 
pooled dataset, in paper IV. Different values of factors from small cross-validations have also 
been reported74,75,77, Table 1. In the pooled dataset (in paper IV) the ratio was calculated 
based on more samples, leading to a higher factor which is considered more accurate and thus 
the factor suggested for the conversion of VPA DBS concentrations. The variation in 
conversion factor does not seem to affect the clinical evaluation of the samples for VPA.  
6.2.2 Tests of agreement 
Lin´s concordance coefficients158 were between 0.901 ̶  0.954 for the four analytes, after 
conversion for CBZ and VPA (paper IV, table 1), which can be interpreted as moderate to 
substantial correlation132. Additionally, the Bland-Altman plots showed that 89% of CBZ and 
93 % of VPA comparisons were within ± 20 % (paper IV, Figure 3). There were, however, 
deviations greater than ± 20 % in several comparisons for LTG and LEV, although the 
acceptance limits for cross-validation from EMA were met.  
 For LTG, the differences in the therapeutic range were demonstrating that LTG DBS 
concentrations were higher than the measured plasma concentrations, except in the low range 
where they were lower, paper II, Fig 2 and paper III, Fig 3. One solution to achieve better 
agreement in the mid and higher range would be to use a factor also for LTG. A conversion 
with a factor would have a negative effect in the lower range (<3µg/mL), since the bias for 
LTG was concentration dependent.  
6.2.3 Effects of different Hct in the child population 
The mean measured Hct in capillary blood in this child population was 0.37 L/L (standard 
deviation 0.025) and the bias related to Hct was negligible, (paper II). When calculating an 
estimated plasma concentration in paper II, we concluded that the individual Hct could be 
replaced by an average Hct of 0.37 L/L since the concentration (µg/mL) differences after Hct 
adjustment were small, mean difference in % for CBZ was 0.14, LTG 0.43 and VPA 3.14, 
see Supplementary 7, paper II. Extreme Hct values can still give rise to bias outside the 
accepted limits, thus children expected to have deviating Hct should not be candidates for 
home sampling.  
6.2.4 Clinical evaluation 
The studied population was children between 2 ̶ 18 years old with a mean age of 9. 
Approximately 15% were on polytherapy, with VPA+LTG as the most frequent combination. 
The population covered different seizure types and ~30% had different concomitant 
diagnoses  
In paper IV, three clinicians did an evaluation of 190 sample pairs in three steps by 
independently sorting the different concentrations into different categories and finally judging 
if the recommendation of drug treatment, based on a DBS or a plasma concentration, would 
have differed for any of the patients included in this study. As described previously (section 
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2.4.1), the included AEDs have broad therapeutic ranges and the drug treatment must be 
related to the individual patient considering possible co-medications that may cause drug-
drug interaction effects.  
Results of the clinical evaluation showed that difficulties with different recommendations 
arose mainly in the concentration range where there is a risk of adverse effects, Figure 11. 
From a total of 190 comparisons, two patients on LTG (4.2%) and two patients on VPA 
(2.9%) could be at risk of obtaining different clinical interpretations, depending on which 
method (DBS or plasma) that was used, see Table 2 in paper IV. From a clinical point of 
view these differences were not dramatic. As a precaution for patients that wish to choose 
self-sampling with DBS, a follow up sample in plasma is recommended if the DBS result 
deviates from expected concentration or if there is a sign of adverse effects, especially at 
critical concentration ranges.  
 
Figure 11. Samples failing criteria of cross validation and clinical evaluation of plasma and DBS samples (total 
of n=190 comparisons). Sample pairs that fail criteria for clinical evaluation are shown above the scale and 
sample pairs that fail cross validation criteria (more than 20% deviation from mean) are shown below the scale. 
Plasma results are filled circles and DBS results are hollow circles. A dotted line indicates that the same sample 
pair failed in both clinical evaluation and cross validation. CBZ=carbamazepine, LTG=lamotrigine, 
LEV=levetiracetam, VPA=valproic acid (re-printed from paper IV with permission) 
The clinical evaluation concluded that self-sampling with DBS can be used as an alternative 
sampling strategy for CBZ, LTG and VPA for children with epilepsy. LEV had a few 
deviations over the whole concentration range and more samples are needed to evaluate if 
these differences arose randomly. The recommendation is to use DBS concentrations for 
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LEV only for compliance queries and in those patients where a traditional venous sample is 
not an option. The therapeutic range for LEV suggested in the literature is variating26,159,160. 
At the TDM laboratory, half of the concentrations are between 8.4 ̶ 22 µg/mL. Large inter-
individual differences are seen for LEV and one contributing factor for variation may be due 
to different concentrations in plasma if blood has not been promptly centrifuged due to in situ 
metabolism156.  
In general, many DBS methods have been developed and validated but results from bridging 
studies with patient samples have rarely been reported. It is important to perform clinical 
validations on capillary patient samples to ensure that the method can be used with patients.  
There is a scarcity of DBS methods that have been developed and implemented in routine 
laboratories161. Other clinical evaluations or validations described in the literature are not 
including clinical assessment. Beyond using cross-validation limits from EMA or other 
organizations we have also put the results in a clinical context and evaluated the differences 
between the methods in relation to TDM in the individual patient. 
6.3 DBS AS A SELF-COLLECTION METHOD FOR PATIENTS 
Patient perspective 
6.3.1 Comparison of sample quality, nurses versus guardians 
In paper IV we compared two groups, nurses (n=25) and guardians (n=86), and we could see 
no difference in sample quality between the groups as the null hypothesis could not be 
rejected by Fisher´s exact test. From the DBS samples obtained by the guardians in the 
hospital, 2.3% were rejected due to sub-optimal quality compared to 8% in the nurse group.  
The result implies that this group of guardians can collect a DBS sample from their children 
with acceptable quality, even though many of these children had concomitant diagnoses that 
made the collection difficult. In other studies where samples from children were collected at 
home and sent by mail to the laboratory, a much higher rate of failed samplings were 
reported18,95. Collecting DBS samples at home may meet its own challenges. It remains to be 
proven, if the guardians in this group can also provide acceptable samples when collected in 
their homes without a nurse advising them. The video instruction and the thorough training 
these guardians received in combination with their motivation to perform correctly, were 
identified as contributing factors for the successful samplings, paper V. Others have referred 
to improved instruction as a way to increase the rate of successful DBS samplings18,95,162. 
In paper IV and V, we prepared for self-sampling at home by developing effective self-
instructive materials for guardians and children with epilepsy1. Results showed that guardians 
to children with epilepsy can collect DBS samples of acceptable quality and the aim to offer 
DBS collection at home instead of traditional collection at the hospital is a feasible 
alternative.  
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6.3.2 Benefits of DBS collection at home 
No earlier studies have investigated the guardian´s perspective on DBS self-sampling at 
home. Some studies have collected data from questionnaires where the guardians and 
children graded the difficulty in performing self-sampling and preferability of DBS home 
sampling versus venous sampling at the hospital18,95,163. By using mixed-methods in paper V, 
we aimed to fill the gap of missing knowledge, where individual experiences could help to 
find knowledge on why or how the sampling can be successful. 
Results from the questionnaire (paper V) suggested that 80% in this group of children and 
their guardians found DBS collection at home desirable after performing the first self-
collection. The results from the questionnaire were in general positive as the participants were 
positively predisposed to the idea of self-sampling at home. On the other hand, it would have 
been difficult to investigate experiences and thoughts in a group with a low interest in 
performing the self-sampling at home. The participants can be seen as a subpopulation from 
the group of guardians and children who are interested in future home sampling. The 
response rate was high, out of 72 possible answers, only 8 were missing. 
In the interviews, reasons for DBS collection that the guardians emphasized as important to 
make everyday life easier were identified. Self-collection of DBS at home, means reduced 
number of hospital visits and this contributes to less stress for both children and guardians. 
Economic factors, both on a private but also on a societal level, were another main reason. 
Reduced stress for the children, more flexibility for sampling and being in a relaxed home 
environment were identified as important factors. A population-based study on health-related 
quality of life in active childhood epilepsy found that anxiety, polytherapy with several AEDs 
and difficulties with school attendance were associated with reduced life quality164. Other 
studies point out that children with epilepsy and concomitant diagnosis and their guardians is 
a vulnerable group that have needs like home based care, increased autonomy and help to 
decrease anxieties, both for children and guardians165–167. In paper V, results suggest that 
DBS collection for TDM at home can assist in satisfying some of the needs identified in these 
studies. In the study, paper V, many children with neurobehavioral and cognitive 
impairments were included. 
Another advantage brought up regarding DBS collection was the possibility to perform 
repeated samplings. Children with several AEDs and problems with seizures, need 
particularly frequent contact with health care institutions and effective TDM (more frequent 
sampling) might help to find the correct individual dose when epilepsy treatment is 
problematic. Guardians to children with epilepsy reported lack of continuity of care as 
problematic in one study167.  
In conclusion, possibility of DBS collection at home has been shown to be very desirable in 
this group of children with epilepsy, and guardians identified many advantages coupled to 
DBS collection at home that can reduce stress and burdens. These findings support that for 
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this group of patients, there is a requirement for alternative sampling that can be performed at 
home. 
6.3.3 Contributing factors for successful DBS self-sampling  
In paper V and Table 3, we identified important factors for successful self-sampling of DBS. 
We found that it was easier to collect a DBS sample if guardians and children with epilepsy 
feel confident and comfortable in the sampling situation. Identified factors for contributing to 
this were; prepared guardians, instructive training material (pedagogic and in diverse 
formats), the possibility to communicate without conflicts or fears, positive and pragmatic 
attitude and willingness to take on the new role as performer. Fulfilling these criteria decrease 
the risk of encountering problems in the sampling situation.  
The knowledge and information generated as a result of the mixed-method study in paper V, 
can assist when creating education material as well as preparing nurses in their roles as future 
educators in DBS sampling168.  
Although video instruction can be effective, especially when learning practical procedures102, 
we learned that providing information concerning the emotional aspects of self-sampling is 
often relegated. Questions related to feelings that may overwhelm the child or the guardian in 
the sampling situation remain unanswered The instruction videos or information by nurses 
can be improved by preparing the guardians not only in a practical manner but also regarding 
what feelings may arise in different situations.  
In paper V, results showed that a comfortable environment built on trust was very important 
for the families involved, especially with children having concomitant diagnoses, where 
routines and a well-known environment affect their wellbeing. The training with a combined 
video instruction and a nurse they knew and were already familiar with was helpful in 
creating a trustful and calm situation for learning. Even though blood sampling might be less 
difficult in the future, because of improvements of sampling devices, the mixed-method study 
suggested that the practical training, with a nurse including support and feedback, during the 
first training occasion is important. With this thorough instruction the guardians can feel 
comfortable when later performing self-sampling at home.  
The mixed-method design and especially the qualitative method with interview data provided 
complementary information that was missing from earlier studies on DBS self-sampling. The 
findings that self-sampling at home was desirable and that a majority could perform it 
without problems have also been reported by others18,95, but how individual guardians felt 
and how children reacted were new interesting aspects that are important to consider when 
optimizing education and information in the future. These important findings could have 
gone unnoticed without a qualitative study. It is also valuable to identify unsuccessful 
samplings as these are not cost-effective and can have considerable impact from a societal 
perspective16. 
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The aim to develop self-instructive material and an effective training for collection of DBS-
samples has been achieved. Knowledge on how to improve the training to be adapted to this 
specific patient group has increased the possibility to collect successful DBS sampling in the 
future. 
Societal perspective 
Patient participation in health care is a societal aim that can improve health outcome and 
reduce costs. Cost-effectiveness has been studied and is also an important aspect of DBS 
sampling. In a recent study, self-sampling with DBS was shown to reduce costs up to 
approximately 2.5 times compared to traditional sampling by a professional at a hospital16. 
The savings in costs were mainly seen in loss of productivity for guardians and travel costs. 
The frequency of sampling affects the overall cost effectiveness, but DBS-collection was 
already cheaper after two samplings, even when a nurse had been designated for training of 
the sampling16. 
Positive examples of improved health care in remote areas within Sweden have been 
reported169,170 and these examples can be used to exemplify how TDM in combination with 
DBS collection can provide better patient care. The research performed during this thesis is 
essential also from a societal perspective since it can help patients to be involved in their 
treatment, be more autonomous and reduce costs. Even if costs can be reduced, it is of 
importance to underline that the patient is in focus and always has the possibility to choose. 
For some patients, sampling at a clinic or hospital is more convenient than self-sampling at 
home. The choice to perform self-sampling at home must not exclude anyone, i.e. instruction 
videos, practical training or other instruction material must be understandable and accessible 
for all patients. 
 
 
 
 
 
 
 
 
 
 
 
 44 
7 CONCLUSIONS 
In this thesis, DBS as a possible matrix for AEDs in children with epilepsy was investigated. 
The self-sampling process was studied to be able to prepare for DBS self-sampling at home 
for this patient group. The findings can be valuable for researchers, professionals in 
laboratory medicine, nurses, clinicians, and children with epilepsy and their guardians as well 
as other patient groups depending on TDM. 
  Simple and rapid LC-MS/MS methods with DBS as matrix for use in a routine 
laboratory were developed and validated for four commonly used AEDs. 
 
 DBS collection on Whatman 903 filterpaper can be applied if the patient samples are 
within Hct ranges of 0.35 ̶ 0.50 L/L and blood drop volumes between 15 ̶ 50 µL.  
 
 Analytes were stable on Whatman 903 filter paper up to one year in ambient 
temperature, can tolerate extreme temperatures and can be transported with normal 
mail service in envelopes with a low risk of bias on the measured concentrations.  
 
 Based on comparison studies from 190 sample pairs from collected capillary DBS 
and plasma the bioanalytical cross-validation was accepted for the four AEDs, 
although including a few large deviations for LEV and LTG. 
 
  Cinical evaluation found risk of generating a different TDM recommendation for 
DBS and plasma concentrations in only 4 out of 190 comparisons. 
 
 DBS samples can be collected through self-sampling by the guardians or older 
children and TDM decisions for CBZ, LTG and VPA can be made in a safe manner.  
 
 LEV collected as DBS can be an option for compliance queries. 
  
 To choose DBS sampling at home as an alternative of plasma concentrations drawn at 
a hospital can be of value to guardians and children with epilepsy and concomitant 
diagnoses.  
 
  Guardians of children with epilepsy are willing and able to collect DBS samples of 
acceptable quality.  
 
  Stress factors in everyday life can be reduced if the possibility of self-sampling at 
home can be offered. Time and money can be saved for individuals as well as for 
society. 
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8 FUTURE PERSPECTIVES 
8.1 USE OF DBS AND SELF-SAMPLING FOR TDM 
As pointed out earlier in section 6.2.4, very few methods for TDM have been implemented 
using DBS as an alternative matrix in routine laboratories. The most suitable drugs for 
implementation of DBS collection in the routine laboratory are perhaps immunosuppressive 
drugs, where the patients are required to collect samples frequently during a long period of 
time. Since routine analysis of immunosuppressant drugs are done in whole blood, it is more 
straight forward to create DBS methods and compare results, than drugs analyzed in plasma 
or serum.  
A disadvantage that is often mentioned is that the transplanted patients need to be monitored 
for other endogenous biomarkers, and as long as this is not possible with DBS, the patient 
still has to collect a venous blood sample. As a result, the benefits with home sampling can be 
realized when only drug concentrations are needed. On the other hand, many DBS methods 
for biomarkers and large molecules have been developed2 and it should be possible to use one 
DBS collection for many types of analyses. A DBS sample, with up to 5 blood spots could be 
separated and used for analysis of for example, creatinine, glucose and transaminases at the 
clinical chemistry laboratory and for TDM at the clinical pharmacology laboratory. This 
approach can be of interest for patient groups that are routinely utilizing blood tests for 
monitoring171. 
Other TDM groups that can be of interest for self-sampling at home in the future are drugs 
with anticoagulant effect, NOAKs like apixaban, dabigatran, edoxaban and rivaroxaban. 
Monitoring of these drugs might be important to increase effectiveness and decrease adverse 
effects and adherence172. Different endogenous measurements also have to be monitored in 
combination for these patients and a DBS test with several spots for analysis of different 
laboratory tests would be practical173. 
8.2 DBS AND AUTOMATION 
There are several commercially available sample work up automations for DBS161. The main 
advantages with an automation for DBS in TDM as an alternative sampling method, would 
be the sample traceability and to decrease the risk of manual mistakes. To increase the 
throughput and decrease turnaround time may not be the most important for DBS that were 
collected in a home environment and sent by mail to the laboratory. This process takes 
several days and therefore the primary aims for these samples are not fast analysis. 
The automated systems are built on flow through desorption or on-line horizontally surface 
sealed extraction. In some of the methods internal standard can be sprayed onto the filter 
paper before extraction. Automatic systems for producing calibrators and QCs have also been 
developed and may be interesting for laboratories that handle many DBS samples174. 
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8.3 VOLUMETRIC DBS 
In the last five years, there has been development of blood sample collection systems with 
separation of a defined volume from the deposited blood drop. The analysis of the entire spot 
instead of a sub-punch also eliminates the Hct bias155. Such a volume defined, whole spot 
collection device for DBS has been developed62,175 and used for parallel collection with 
Whatman 903, in smaller projects at the clinical pharmacological laboratory.  
These developments are promising for the future since the known bias can be decreased. 
Most of these devices are designed to be easier for the patients to use in the self-collection 
situation. A disadvantage is that the cost of such a device might increase the costs for health 
care in comparison with the conventional filter paper and is consequently not a first choice 
for development countries in need of TDM. On the other hand, total savings in health care are 
to be expected (see section 6.3.3) if self-sampling at home can be used and the new 
developed devices are cost effective compared to perform the sampling at a clinic or a 
hospital.  
8.4 OTHER MATRICES FOR SELF-SAMPLING AT HOME 
For TDM and AEDs there is also a possibility of using other matrices for home sampling. 
Studies on AEDs and saliva have shown promising results for some AEDs176. The saliva 
sampling, however, include many uncontrollable factors and the sample can easily get 
contaminated. Methods for collection and automated separation of plasma on the filter paper 
(dried plasma spots) has been developed and is of interest in TDM61,177–179. This alternative 
might be favorable for drugs such as VPA that are mostly abundant in the plasma fraction 
because the extracts will probably be more comparable with routine plasma samples. If free 
fraction of the drug can be separated from the plasma fraction directly to the filter paper, it 
would be an interesting alternative for some drugs. Exhaled breath is another possible 
alternative that has not yet been thoroughly investigated for TDM of drugs180. 
8.5 DBS COLLECTION BENEFITS FOR TDM 
DBS self-collection can facilitate larger studies related to TDM and research infrastructure 
becomes easier when repeated sampling can be done at home at different time-points. DBS 
collection can also be used for pharmacokinetic studies to improve TDM and develop better 
medicines for children93,181. Adherence and self-monitoring are other possible areas where 
DBS collection can be of value for TDM182. Field studies in countries where for example 
HIV and malaria medicines are most frequently used is needed. DBS can be a good 
alternative to venous sampling in studies to increase knowledge of pharmacokinetics as well 
as for compliance queries. 
Large scale projects for antibiotics and tuberculosis drugs are future potential areas where 
DBS sampling can be valuable for research projects at the clinical pharmacology 
laboratory183. 
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8.6 PATIENT ROLE IN THE FUTURE 
There is a trend of increased patient participation and engagement in health care, such as the 
availability of kits for home testing, possibility to meet a doctor via the internet, order 
laboratory tests and see results from laboratory analysis in the electronic journal184. These 
relatively new ways to communicate and interact with the health care system have many 
advantages for patients living far away from hospitals or for patients with difficulties of 
transportation169,170. The new role of the patient also affects nurses, clinicians and other health 
care practitioners who will have to put more effort into the education and information of 
patients in the future. As a result of this, programs for instructions and information of patients 
are interesting areas for future research. 
Future research projects would be to validate new sampling devices in the patient group and 
evaluate which of the new sampling devices are the most patient-friendly. Another possibility 
would be to collaborate with the companies that develop these devices and prepare automatic 
registration of sampling time. This would increase the effectiveness of TDM sampling, which 
is very much dependent on collection time. Feed-back to the patients when the sample arrives 
at the laboratory is another improvement that patients might ask for. 
If self-sampling and analysis of DBS can be made safely, it is a way to meet the patient needs 
in a modern society and it can help shift the balance in an overburdened health care system. 
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